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Enantiomeric profiling of chiral drug biomarkers in wastewater with the usage 
of chiral liquid chromatography coupled with tandem mass spectrometry 
Erika Castrignanò, Anneke Lubben, Barbara Kasprzyk-Hordern1 
University of Bath, Department of Chemistry, Faculty of Science, Bath, BA2 7AY, UK 
Abstract 
This paper proposes a novel multi-residue enantioselective method utilising a CBH 
(cellobiohydrolase) column, for the analysis of 56 drug biomarkers in wastewater. These are: opioid 
analgesics, amphetamines, cocaine, heroin, stimulants, anaesthetics, sedatives, anxiolytics, designer 
drugs, phosphodiesterase-5 (PDE5) inhibitors, amphetamine and methamphetamine drug precursors. 
Satisfactory enantiomeric separation was obtained for 18 pairs of enantiomers including 
amphetamine, methamphetamine, MDMA (3,4-methylenedioxy-methamphetamine) and its 
metabolites HMA (4-hydroxy-3-methoxyamphetamine) and HMMA (4-hydroxy-3-methoxy-
methamphetamine), PMA (para-methoxyamphetamine), MDA ((±)- 3,4-
methylenedioxyamphetamine ) and mephedrone. The method was applied in a one week monitoring 
study of a large wastewater treatment plant in the UK. Most target drugs were found at quantifiable 
concentrations in analysed samples. Enantiomeric profiling revealed that amphetamine, 
methamphetamine and MDMA were found enriched with R-(-)-enantiomers, probably due to their 
stereoselective metabolism favouring S-(+)-enantiomers. MDA was either enriched with R-(-)- or S-
(+)-enantiomer indicating that its presence might be due to either abuse of racemic MDA or abuse of 
racemic MDMA respectively. Non-racemic enantiomeric fractions were also observed in the case of 
HMMA and mephedrone suggesting enantioselective metabolism. To the authors’ knowledge, this is 
the first time chiral separation and wastewater profiling of mephedrone, PMA, MDMA and its 
metabolites HMA and HMMA have been reported.  
Keywords: chiral drugs, enantiomers, chiral chromatography, wastewater, wastewater-based 
epidemiology, illicit drugs 
1. Introduction 
Wastewater-based epidemiology (WBE) has the potential to inform public health via the analysis of 
human urinary biomarkers in wastewater [1]. WBE is an emerging field but it has already found 
applications in verifying spatial and temporal community-wide illicit drug [2, 3], alcohol [4] or 
tobacco use [5]. 
An understanding of human pharmacokinetics and the selection of potential biomarkers informing 
public health is key to successful application of the WBE approach. As human pharmacokinetics 
shows stereoselectivity in the case of many chiral xenobiotics [6], chirality is also important to 
investigate in WBE.  
In a recent study, the enantioselective separation of common illicit drugs revealed changes in 
enantiomeric composition of chiral drugs during wastewater treatment [7, 8]. In particular, it was 
demonstrated that the type of chiral drug, the treatment technology used in a wastewater treatment 
plant and the season affected the stereoselective enrichment or depletion of the enantiomeric 
composition of a drug. In another study, microbial metabolic processes were found to be  responsible 
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for stereoselective degradation of amphetamine-like compounds in river [9] and activated sludge 
microcosms [10]. 
Unfortunately in WBE, chiral analysis still has limited application despite its high potential in helping 
to understand for example: (i) the different route of synthesis of the drugs, (ii) the differentiation 
between the abuse and the licit use of drugs, (iii) the origin of a drug residue, differentiation between 
consumption and disposal of unused drugs and (iv) and the potency of the abused drug [11]. The 
concept of enantiomeric profiling in WBE has been applied for the first time by Kasprzyk-Hordern 
et al. (2012) [11]. In fact, from a study conducted in 7 WWTPs in England for 5 months, it was 
possible to conclude that MDMA was found in the influent wastewater samples due to its abuse rather 
than its direct disposal. Also, the presence of MDA was associated with abuse of MDMA and not 
abuse of MDA. In another study by Emke et al. (2014) [12], chiral analysis was key in confirming 
that unexpectedly high loads of MDMA observed in wastewater from one of Dutch cities were a 
result of dumping of MDMA from a local production facility during a police raid.  
In order to undertake enantiomeric profiling of wastewater for chiral drug biomarkers, robust and 
multi-residue chiral analytical methods need to be developed. Until now, chiral LC-MS (liquid 
chromatography coupled with tandem mass spectrometry) methods were utilised in the investigation 
of a limited number of chiral drugs [11-13]. Therefore, chiral methods were used only as 
complementary tools alongside non-chiral LC-MS methods. Those approaches required an ad hoc 
sample preparation, which meant higher sample volume, more time consuming and less cost effective 
analysis.  
This paper proposes, for the first time, a multi-residue method utilising a CBH (cellobiohydrolase) 
column for the analysis of 56 drug biomarkers at enantiomeric level, including satisfactory 
enantiomeric separations for 18 pairs of enantiomers. To the authors’ knowledge, this method is the 
first to allow for: 
(i) simultaneous and mutiresidue differentiation between the abuse and the licit use of drugs 
(e.g. in the case of amphetamine as illicit amphetamine, as opposed to prescribed licit 
amphetamine, is distributed as racemate),  
(ii) verification of the origin of a drug residue (e.g. methamphetamine as chiral signature of 
methamphetamine is route of synthesis dependent),  
(iii) differentiation between consumption and disposal of unused drugs (e.g. in the case of 
MDMA, fluoxetine and other targeted chiral illicit drugs. This is due to the fact that 
metabolic processes in humans are stereoselective and lead to changes of chiral signature 
of excreted drugs when compared to their unused counterparts) 
(iv) verification of the potency of the abused drug (e.g. S-(+)- enantiomers of amphetamine 
and methamphetamine are known to be much more potent than R-(-) enantiomers of the 
same drugs). 
The developed and validated method enabled the identification, detection and quantification of most 
targeted human biomarkers in wastewater. The method was applied in a one week monitoring study 
of a large wastewater treatment plant in the UK. Wastewater profiling of 56 biomarkers was 
undertaken. These are: opioid analgesics, amphetamines, cocaine, heroin, stimulants, anaesthetics, 
sedatives, anxiolytics, designer drugs, PDE5 inhibitors, amphetamine and methamphetamine drug 
precursors (Table 1). To the authors’ knowledge, this is the first time chiral separation and then 
wastewater profiling of mephedrone, MDMA and its metabolites HMA, HMMA, PMA (para-
methoxyamphetamine) using chiral CBH-HPLC-MS/MS method has been reported. The latter 
compound is a phenylisopropylamine with hallucinogenic properties, responsible, alongside N-
monomethyl analogue (PMMA), for several deaths due to its abuse [14-16].  
2. Experimental 
2.1.Chemicals and materials 
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The following analytes were selected for the study (Table 1): opioid analgesics, amphetamines, 
cocaine, heroin, stimulants, anaesthetics, sedatives, anxiolytics, designer drugs, PDE5 inhibitors, 
amphetamine and methamphetamine drug precursors. Table S1 shows all target analytes, their CAS 
number, molecular formula, molecular weight, pKa and supplier information.  
The following deuterated analogues of target analytes were used as internal standards (IS): 
cocaine-d3, benzoylecgonine-d8, cocaethylene- d3, ecgonine methyl ester- d3, amphetamine-d5, 
methamphetamine-d5, phencyclidine-d5, mephedrone-d3, MDA-d5, MDMA-d5, MDEA-d5, 
cotinine-d3, EDDP-d3, heroin-d9, codeine-d6, oxycodone-d6, hydrocodone-d6, morphine-d6, 
morphine-3β-D-glucuronide-d3, methadone-d9, temazepam-d5, diazepam-d5, nordiazepam-d5, 
nitrazepam-d5, oxazepam-d4, lorazepam-d4, zopiclone-d4, ketamine-d4, norketamine-d4 and 1S,2R-
(+)-ephedrine-d3. 
The following analytes were used as racemates: (±)-mephedrone, (±)- 4-hydroxy-3-
methoxymethamphetamine (HMMA), (±)- 3,4-methylenedioxymethamphetamine (MDMA), (±)- 4-
hydroxy-3-methoxyamphetamine (HMA), (±)- methamphetamine, (±)- amphetamine, (±)- 3,4-
methylenedioxyamphetamine (MDA), (±)- tramadol, (±)- desmethylvenlafaxine, (±)- venlafaxine, 
(±)- 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), (±)- ephedrine, (±)- pseudoephedrine, (±)- 
para-methoxyamphetamine (PMA), (±)- norephedrine, (±)- norfluoxetine, (±)- zopiclone, (±)- 
fluoxetine, (±)- 3,4-dihydroxymethamphetamine (DHMA), (±)- methadone, (±)- ketamine, (±)- 
norketamine, (±)- 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), (±)- lorazepam, (±)- 
temazepam, (±)- oxazepam. Enantiomerically pure standard solutions were used for the following 
analytes: 6-monoacetylmorphine with five defined stereocentres; oxycodone with four defined 
stereocentres, also known as (-)-oxycodone; morphine-3β-D-glucuronide with ten defined 
stereocentres; hydrocodone with four defined stereocentres; dihydromorphine with five defined 
stereocentres; codeine, also known as (-)-codeine with five defined stereocentres; morphine, also 
known as D-(-)-morphine with four defined stereocentres; normorphine with five defined 
stereocentres; heroin with five defined stereocentres; dihydrocodeine, also known as (-)-
dihydrocodeine with five defined stereocentres; noroxycodone with four defined stereocentres; 
oxymorphone, also known as (-)-oxymorphone with four defined stereocentres; cocaethylene with 
four defined stereocentres; cocaine, also known as (-)-cocaine with four defined stereocentres; 
benzoylecgonine, also known as (-)-benzoylecgonine with four defined stereocentres and 
anhydroecgonine methyl ester (AEME) with two defined stereocentres. 
All standards and internal standards were of the highest purity available (>97%). Stock and working 
solutions of standards were stored at -20° C. Methanol, acetonitrile and ammonium acetate were 
purchased from Sigma Aldrich, UK. Ultrapure water was obtained from PURELAB UHQ-PS Unit 
(Elga, UK). The deactivation of the glassware was carried out in order to prevent the adsorption of 
polar compounds to the hydroxyl sites on the glass surface. The process consisted of the following 
steps: rinsing of the glassware with 5% DMDCS once, with toluene twice and with methanol thrice.  
2.2.Sample collection, storage and sample preparation 
24h time-proportional (10 mL every 15 minutes) composite wastewater influent samples were 
collected in PTFE bottles from a local wastewater treatment plant. They were then transported to the 
laboratory in cool boxes packed with ice blocks and filtered through GF/F 0.7 µm glass fibre filter 
(Whatman, UK). 100 µL of a mixture of internal standard at concentration 1 mg L-1 were added to 
100 mL of a wastewater sample to give final concentration of 1 µg L-1. Stability of analytes in 
wastewater has been already investigated in our previous work [17, 18]. 
Solid phase extraction (SPE) was carried out using Oasis HLB cartridges (60 mg, Waters, UK) and 
the following procedure. The cartridges were conditioned with 2 mL of methanol followed by 
equilibration with 2 mL of ultrapure water at a rate of 3 mL min-1. 100 mL of environmental sample 
(spiked with ISs at 1 µg L-1) were passed through the HLB cartridge at a rate of 8 mL min-1. The 
cartridges were then washed with 3 mL of ultrapure water at a rate of 3 mL min-1 and the analytes 
were eluted with 4 mL of methanol at a rate of 8 mL min-1 into 5 mL silanised glass tubes. The extract 
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was transferred to the TurboVap evaporator (Caliper, UK). After evaporation to dryness under 
nitrogen flow (5-10 psi) at 40°C the samples were reconstituted with 0.5 mL 1mM ammonium 
acetate/methanol 85:15 v/v and filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 13mm). 
The filtered samples were transferred to polypropylene plastic vials bonded pre-slit PTFE/Silicone 
septa (Waters, UK) and then 20 µL were directly injected into a UHPLC-MS/MS system. Samples 
from monitoring campaign were prepared in duplicate and analysed twice.  
2.3. Sample analysis with chiral liquid chromatography coupled with tandem mass spectrometry 
Separation of all analytes was undertaken with Waters ACQUITY UPLC® system (Waters, 
Manchester, UK). Three chiral columns were evaluated in this study:  (1) CHIRALPAK® CBH 
HPLC Column 5 μm particle size, L × I.D. 10 cm × 2.0 mm (Chiral Technologies, France) with a 
Chiral-CBH guard column 10 × 2.0 mm, 5 μm particle size (Chiral Technologies, France); (2) 
CHIROBIOTIC V column 5 μm particle size, L × I.D. 25 cm × 2.1 mm (Sigma Aldrich, UK) with a 
guard column 2 cm × 4.0 mm, 5 μm particle size (Sigma Aldrich, UK); (3) CHIROBIOTIC T column 
5 μm particle size, L × I.D. 25 cm × 2.1 mm (Sigma Aldrich, UK) with a guard column 2 cm × 4.0 
mm 5 μm particle size (Sigma Aldrich, UK).  
ACQUITY UPLCTM autosampler was kept at 4°C, while the column temperature was set at 25°C. 
The injection volume of the sample was 20 µL. Several mobile phase compositions were tested (see 
Tables S2, S3 and S4 for details). Different flow rates were also trialled: 0.075 mL min-1 and 0.1 mL 
min-1. The selected chiral column was the CHIRALPAK® CBH HPLC column. The chosen mobile 
phase used in the method was 1mM ammonium acetate/methanol 85:15 v/v at a 0.1 mL min-1 under 
isocratic conditions. 
All analytes were identified and quantified using a triple quadrupole mass spectrometer (Xevo TQD, 
Waters, Manchester, UK) equipped with an electrospray ionisation source. Analyses were performed 
in positive mode with an optimised capillary voltage of 3 kV, source temperature of 150°C, 
desolvation temperature of 265°C and desolvation gas flow of 550 l h-1. Nitrogen, supplied by a high 
purity nitrogen generator (Peak Scientific, UK), was used as a nebulising and desolvation gas. Argon 
(99.999%) was used as a collision gas. MassLynx 4.1 (Waters, UK) was used to control the Waters 
ACQUITY system and the Xevo TQD. Data processing was carried out on TargetLynx software 
(Waters, Manchester, UK).   
The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode measuring 
the fragmentation of the protonated pseudo-molecular ions of each compound. The choice of 
fragmentation ion for each compound was based on the most intense signal. MRM transitions as well 
as cone voltages and collision energies were obtained after direct infusion of each standard at a 
concentration of 100 µg L-1 into the mass spectrometer. In the final stage of the method development, 
once CBH column was chosen, cone voltages and collision energies were optimised for the chosen 
MRM transitions through infusion of each standard at 100 μg L-1 combined with LC using 1mM 
ammonium acetate/methanol 85:15 v/v as mobile phase at 0.1 mL min-1 under isocratic conditions. 
Two or three MRM transitions were selected for each compound. The most abundant transition 
product ion was typically used for quantification with second and third transitions, for nearly all 
compounds, used for confirmation purposes. The MRM transitions of the studied compounds, cone 
voltages and collision energies are presented in Table 2.  
Selection of internal standards (see Table 3) for those compounds for which deuterated or C13 
analogues were not available commercially or in our laboratory was based on structural similarity 
and elution time to account for possible signal suppression/enhancement of studied analytes in ESI.  
2.4.Method validation 
The developed method was fully validated for wastewater samples. The following parameters were 
studied: instrumental and method limits of detection and quantification, linearity, precision and 
accuracy, ion suppression, resolution of enantiomers and enantiomeric fraction. Due to the potential 
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presence of target analytes in wastewater deuterated analogues of the targeted analytes were used as 
internal standards and to evaluate method performance. 
The instrumental limit of detection (IDL) was determined at a concentration value giving a signal-to-
noise ratio (S/N) ≥ 3 for all the MRM transitions selected for each substance. The method detection 
limit (MDL) was calculated using the following formula:  
 
 
CFc
IDL
MDL



Re
100
    (1) 
where IDL is the instrumental limit of detection, Rec is the relative SPE recovery of the analyte in the 
matrix and CF is the SPE concentration factor. 
The instrumental limit of quantification (IQL) was determined at the minimum concentration value 
giving S/N ≥ 10 for all the MRM transitions. The method quantification limit (MDL) was calculated 
using the following formula: 
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IQL
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    (2) 
where IQL is the instrumental limit of quantification, Rec is the relative SPE recovery of the analyte 
in the matrix and CF is the SPE concentration factor. 
The linearity of the method was verified for each compound in the following range: IDL - 1000 µg 
L-1. The individual calibrators were at a concentration of 1000, 800, 700, 600, 500, 400, 300, 200, 
100, 50, 10, 5, 1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.01, 0.005 and 0 µg L-1. 
For some compounds, especially human indicators, such as caffeine and creatinine, dilution integrity 
was considered as these substances are present at high concentrations in wastewater in respect to the 
illicit drugs concentration range. Dilution integrity was assessed through the analysis of two diluted 
samples 1:10 and 1:100 at the highest concentration in wastewater spiked with a mixture of ISs. If 
the compound could be quantified with a relative error within the 15% in relation to the nominal 
concentration, the dilution integrity was maintained. 
Precision, expressed as relative standard deviation (RSD) of replicate analysis (n=4) at three different 
concentrations on the same day (intra-RSD%), was evaluated as:  
(i) instrumental precision using standard solutions spiked in mobile phase at 10, 100 and 1000 
µg L-1 for (non-chiral/not enantiomerically separated) analytes, or at 5, 50 and 500 µg L-1 
for individual enantiomers (separated from racemic mixture);  
(ii) method precision using standard solutions spiked in 100 mL of influent wastewater at 50, 
500 and 5000 ng L-1 for (non-chiral/not enantiomerically separated) analytes, or at 25, 250 
and 2500 ng L-1 for individual enantiomers (separated from racemic mixture). The 
extraction by SPE of these samples followed the same protocol described in 2.2. 
Reproducibility (inter-day precision) of the method was determined by replicate measurements (n=3) 
of the same concentrations of analytes as in the case of intra-day precision on three different days in 
order to assess the inter-day instrumental precision and the inter-day method precision. Precision data 
were acceptable when the RSD% was less than 15% for all the concentrations investigated during the 
different days.  
Accuracy of the method was expressed as percentage of closeness agreement between the mean of a 
set of analytical results and the theoretical value. 
Carryover was studied by injecting a spiked sample at a concentration of 1000 µg L-1 followed by 
three blanks and it was considered insignificant if the concentration of the analyte was below the 
LOQ. 
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Ion suppression was calculated for each analyte as a percentage decrease in signal intensity in a 
sample matrix versus in mobile phase (free from analytes). Signal suppression was calculated using 
the following equation: 
  100*1% 




 

MPI
IoIs
nsuppressioSignal      (3) 
where IS was the analyte peak area in wastewater extract (0.5 mL) spiked after SPE extraction with 
100 ng, I0 was the analyte peak area in unspiked wastewater extract, IMP was the analyte peak area in 
mobile phase (0.5 mL) spiked with 100 ng of each analyte.  
Resolution of enantiomers of chiral drugs (Rs) was calculated using the following equation:  
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where trE1 and trE2 are retention times of the first- and the second-eluted enantiomer respectively and 
wbE1, wbE2 are widths of their responses at a baseline. Rs ≥1.2 indicates full baseline resolution. Rs =1 
indicates 2% overlap which is deemed acceptable for quantification purposes. 
Enantiomeric fraction (EF) was calculated using the following equation: 
 
    

EF                             (5) 
where (+) is the concentration of (+)-enantiomer or first eluted enantiomer, and (-) is the concentration 
of (-)-enantiomer or second eluted enantiomer. EF equals 1 or 0 in the case of enantiomerically pure 
compound, and 0.5 in the case of a racemate. The assessment of the absolute configuration of the first 
eluted or second eluted enantiomer was achieved through the injection of an enantiomerically pure 
standard (when available). 
Validation protocols were in agreement with European Guidelines concerning the performance of 
analytical methods and the interpretation of results [19]).   
2.5.Quantification and quality controls 
The identification criteria for each analyte were as follows [19]: 
- %RSD of relative retention time (RRT) should not exceed ±2.5% when compared to RRT of 
standard solution.  
- All selected MRM transitions need to be present.  
- The maximum permitted tolerance for relative ion intensities of MRM transitions should not 
change more than ±20% for ions with relative intensities of >50%, ±25% for ions with relative 
intensities between 20% and 50%, 30% for ions with relative intensities between 10% and 
20% and ±50% for ions with relative intensities less than 10%. 
Quality controls at 10, 100 and 1000 µg L-1 were also prepared and injected on regular basis to 
maintain instrument’s performance.  
3. Results and Discussion 
3.1.Choice of biomarkers 
Fifty six compounds were selected and targeted as potential human biomarkers of drug consumption. 
These are: opioid analgesics, amphetamines, cocaine, heroin, stimulants, anaesthetics, sedatives, 
anxiolytics, designer drugs, PDE5 inhibitors, amphetamine and methamphetamine drug precursors 
(Table 1). Multiple human urine indicators, such as creatinine, caffeine, nicotine, 1,7-
dimethylxanthine, cotinine, were also targeted as indicators of population size served by a wastewater 
treatment plant in question. 
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The selection process of target drug biomarkers included the investigation of: (i) classical drugs 
of abuse, with good literature based evidence of their detection and quantification in wastewater; (ii) 
new emerging drugs of abuse for further study, even if prevalence data and stability data in 
wastewater are not well documented, and (iii) substances with abuse potential.  
Cocaine, benzoylecgonine, anhydroecgonine methylester and cocaethylene were selected as 
biomarkers of cocaine abuse. Indeed, anhydroecgonine methylester, ethylecgonindine and ecgonidine 
were identified as suitable indicators of crack cocaine [20]. Moreover, cocaethylene was chosen as 
biomarker of co-administration of cocaine and ethanol [21]. Ecgonidine and norcocaine were not 
included in this study as they were not detected in a previous UK study by Baker et al. (2014). 
Furthermore, cuscohygrine, a marker of coca chewing [22], was also included in the method in order 
to distinguish between chewing of cocoa leaves (the “coqueo”, a practise well-known in South 
America) and illegal abuse of cocaine. To the authors’ knowledge, no investigation of cuscohygrine 
and hygrine (cocoa chewing markers) has been undertaken to date. It is however worth mentioning 
that the practise of chewing cocaine is a non-European habit. Cuscohygrine was included in the 
method development but not in the method validation due to low sensitivity and poor chromatography 
(results are included in the supplementary data). 
3.2. Method development for the detection of illicit/licit abused drugs in wastewater 
3.2.1. Chiral-CBH column 
The CHIRAL-CBH column contains a protein cellobiohydrolase (CBH) as the chiral selector which 
is immobilised onto spherical 5 µm silica particles. The protein has a molecular weight of 60,000–
70,000 and an isoelectric point of 3.9. The chiral recognition site is 4Å×7Å×40 Å-long tunnel in the 
core of the protein. The tunnel contains seven acidic amino acid residues, four tryptofan residues and 
also tyrosine, serine, threonine, arginine and histidine. The mechanism of retention of analytes in 
CHIRAL-CBH column can therefore involve a combination of ion exchange, hydrogen bonding and 
hydrophobic interactions. The enantioselectivity of the retention is regulated by the pH of mobile 
phase, the nature and concentration of the organic modifier and the aqueous buffer [7]. Therefore, in 
order to achieve the best chiral recognition of target chiral analytes within one analytical run, the 
following parameters were investigated in this study: type and concentration of organic modifier 
(acetonitrile, methanol an isopropanol) in aqueous mobile phase and concentration of ammonium 
acetate. 
In order to undertake quantitative measurements at enantiomeric level we aimed at obtaining 
enantiomeric resolution with maximum 2% overlap for each pair of enantiomers (Rs≥1). Our study 
revealed that Rs ≥1 was achieved only in the case of 3 compounds (HMA, fluoxetine and zopiclone) 
in 1mM ammonium acetate/acetonitrile 9:1, 7 compounds in 1mM ammonium acetate/isopropanol 
9:1 and >10 compounds in 1mM ammonium acetate/methanol 8.5:1.5 (Figures S1-3). A comparison 
of mobile phases with the same water content revealed that the separation selectivity differed for 
protic and aprotic solvents. Acetonitrile (an aprotic solvent) did not provide an adequate separation 
selectivity as opposed to protic solvents such as methanol and isopropanol (fluoxetine was an 
exception). Moreover, better separation selectivity was observed for more polar methanol than 
isopropanol. Furthermore, the water content in mobile phases containing isopropanol or methanol 
had an impact on enantioselectivity in the case of most of the studied analytes. In fact, lower water 
content provided higher resolution of enantiomers. 
Furthermore, different organic content in aqueous mobile phases affected retention times of many 
compounds as shown in Figure S4. A linear relationship between retention times and the methanol 
content with different concentrations of ammonium acetate was observed. Indeed, retention times 
decreased with higher concentration of ammonium acetate. Furthermore, they decreased with a higher 
concentration of methanol. In contrast, retention times increased with an increase of concentration of 
isopropanol (Figure S5). 
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The salt concentration plays a key role in controlling the pH of mobile phase, ionisation of analytes 
and resulting interactions between analytes and the stationary phase. In this study, ammonium acetate 
was used. The amphetamine-like compounds (except for PMA) showed higher resolution with lower 
concentration of ammonium acetate in the mobile phase. However, this trend was not observed in the 
case of cyclopyrrolone zopiclone and the substituted cyclohexanone norketamine (Figure S3). 
3.2.2. Chirobiotic V and T 
Chirobiotic V and T, two chiral columns having macrocyclic antibiotics as chiral selectors, were also 
tested. In reversed-phase conditions, not only cationic and anionic interactions are possible by 
changing pH of the mobile phase but also inclusion of the pocket and hydrogen bonding are favoured. 
In polar organic mode, other interactions are involved, such as dipole stacking and π-π complexation. 
A comparison between CBH and Chirobiotic V columns was performed by Bagnall et al. 2012 [23]. 
Due to the utilisation of a combination of ion exchange, hydrogen bonding and hydrophobic 
interactions, CBH column was more selective in providing better enantiomeric resolution (i.e. Rs 
MDMA CBH 1.9 > Rs MDMA CBV 1.0) than Chirobiotic V. In general, CBH column provided better results 
in terms of separation and resolution of amphetamine-like compounds when compared to Chirobiotic 
V.  
Experiments carried out with Chirobiotic T column showed higher enantioselectivity (Rs ≥2.2) for 
benzodiazepines only, a class of compounds not enantiomerically resolved using CBH column 
(Figure S5). It is worth emphasising that polar organic mobile phases, containing only methanol and 
99% methanol/0.005% FA/1mM ammonium acetate, provided the best chiral recognition for most of 
the chiral benzodiazepines. Furthermore, mobile phases containing comparable quantities of an acid 
as a mobile phase additive provided better chiral recognition at lower concentrations of ammonium 
acetate (Figure S6). 
 
After taking above results into consideration, the best chiral recognition for the widest group of 
analytes, combined with acceptable retention times, was achieved with the CBH column and a mobile 
phase composed of 1mM ammonium acetate/methanol 85:15 (pH 6.4). 
3.3.Method validation for the detection of illicit/licit abused drugs 
3.3.1 Solid phase extraction 
Oasis HLB cartridges are the sorbents of choice when utilising chiral separations with the CBH 
column. Relative recoveries data are reported in Table 4. Recoveries were high (on average > 90%) 
for all analysed compounds. 
3.3.2. Instrumental and method validation parameters  
Figure 1 shows mass chromatograms of MRM 1 transitions used for quantification purposes, for each 
investigated analyte of a spiked influent wastewater sample at a concentration of 500 ng L-1. The 
developed method allowed for identification and quantification of all studied analytes with 
satisfactory sensitivity and specificity. 
Concentrations of compounds were calculated using the standard calibration curves which were 
developed using a detector response defined as the ratio of the peak ion (the specific product ion of 
the highest intensity, MRM1) to the base peak ion of the internal standard. The mean correlation 
coefficients (R2) of the calibration curves were on average > 0.997 for the investigated compounds 
(Table 5). The linearity ranges varied for different analytes. Most analytes showed linearity from 0.25 
µg L-1 up to 500 or 1000 µg L-1 (for single enantiomer or racemate respectively). Opioids, DHMA, 
lorazepam, creatinine and 1,7-dimethylxanthine showed very good linearity in the range: 1 µg L-1 - 
500 or 1000 µg L-1 (for single enantiomer or racemate respectively). Amphetamine-like compounds 
gave linearity from 0.125 µg L-1 to 500 or 1000 µg L-1 (for single enantiomer or racemate respectively) 
showing a high level of performance of the CBH column for these compounds. Cocaine and its 
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metabolites responded with a linearity range of 0.01 µg L-1 - 500 or 1000 µg L-1 (for single enantiomer 
or racemate respectively). In the case of compounds present in wastewater at high concentrations 
exceeding accepted linearity ranges, dilution (1:10 or 1:100) of samples was utilised. It was 
maintained with a relative error <15%.  
Good enantiomeric resolution (Rs ≥1.0, allowing for quantification of individual enantiomers) was 
obtained for most analytes (Table 6). The following analytes: MDEA, HMMA, tramadol, fluoxetine, 
, ephedrine, norephedrine and desmethylvenlafaxine showed lower enantiomeric resolution and 
therefore results for single enantiomers of these compounds should be considered on a semi-
quantitative basis.  
Enantiomeric fractions for those analytes which were injected as racemates, were on average 0.49 
and were reproducible across different concentration ranges (Table 6).  
The instrumental limits of detection and quantification ranged from 0.005 to 10 µg L-1 and from 0.05 
to 50 µg L-1 respectively (Table 5). The method limits of detection and quantification ranged from 
0.03 to 61 ng L-1 and from 0.13 to 320.87 ng L-1 (Table 5). The instrumental and method precision 
was on average <5% and <10% respectively (Tables 7 and S5). Ion suppression studies showed how 
the presence of the internal standard deuterates compensated the ion suppression in the matrix, even 
for those compounds that had not its corresponding deuterated analogue. (Table S6). 
3.3.3. Analysis of wastewater samples 
The developed and validated method was applied in a one-week monitoring campaign of a wastewater 
treatment plant serving a large city in the UK. The results are provided in Table 8. Most target drugs 
were found at quantifiable concentrations in analysed samples. The results for several drugs such as 
cocaine and MDMA and their metabolites show a clear trend of increased concentration during 
weekends. Other target drugs showed constant concentrations across the sampling week. These are 
for example: morphine, ketamine, benzylpiperazine, dihydrocodeine, methadone, amphetamine and 
methamphetamine. These results will be used in further study to estimate drug use via wastewater-
based epidemiology. It is worth noting that despite suspected high usage of zopiclone, fluoxetine and 
norfluoxetine, these drugs were not detected in analysed wastewater samples. This is probably 
because of relatively high MDL values for zopiclone, fluoxetine and its metabolite norfluoxetine in 
the developed method. 
Amphetamine, methamphetamine and MDMA were found enriched with R-(-)-enantiomers, probably 
due to their stereoselective metabolism favouring S-(+)-enantiomers. MDA was either enriched with 
R-(-)- or S-(+)-enantiomer indicating that its presence might be due to either abuse of racemic MDA 
(excess of R-(-)-enantiomer should be observed if administered as racemate) or abuse of racemic 
MDMA (excess of S-(+)-enantiomer should be observed). As MDA is a minor and not exclusive 
metabolite of MDMA, other metabolites (HMMA, HMA, and DHMA) were targeted for the first time 
in wastewater. The trend observed for HMMA in terms of concentration was similar to the parent 
drug MDMA, whilst for HMA and DHMA the trends were not “superimposable” to that one of 
MDMA. Among the metabolites of MDMA investigated, this was the first time that the enantiomeric 
profiling of HMA and HMMA was studied in wastewater. In the developed method, the enantiomers 
of DHMA were not separated so evaluation of its enantiomeric profiling was not possible. Significant 
changes in enantiomeric fractions (between 0.40 and 0.58) were noticed in the case of HMMA 
suggesting enantioselective metabolism. The enantiomeric profiling of PMA was not undertaken as 
PMA was not detected in wastewater. Even though PMA is a minor metabolite of PMMA, as reported 
by Lin et al.2007, most PMMA is excreted unchanged in the urine. So, PMA could be a suitable 
biomarker only for PMA intake [24]. 
Temporal changes in mephedrone concentrations were observed with noticeable increase of 
mephedrone levels during weekends. This is the first time mephedrone was detected and quantified 
in wastewater in the UK. Mephedrone was also found to be enriched with E1 enantiomer, which 
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suggests enantioselective metabolism in humans. Further work is needed to support the above 
hypothesis.  
Conclusions 
Understanding patterns of drug use is of key importance in public health monitoring. WBE, a new 
non-intrusive tool, provides significant advances in the field. It allows for multiple temporal and 
spatial drug use estimates in near-real time. Enantiomeric profiling provides a new dimension to WBE 
as it can help with the verification of the origin of drug residue, potency of abused drug and its 
synthetic route. To aid enantiomeric profiling in WBE, a new analytical method utilising a CBH 
column and liquid chromatography coupled with tandem mass spectrometry was developed. The 
method showed very good performance: >90% SPE recoveries, very good sensitivity (MDLs and 
MQLs at ppt levels), high linearity range and method precision <10%. The method allowed for the 
analysis of 56 drug biomarkers in wastewater. These are: opioid analgesics, amphetamines, cocaine, 
heroin, stimulants, anaesthetics, sedatives, anxiolytics, designer drugs, PDE5 inhibitors, 
amphetamine and methamphetamine drug precursors. Satisfactory enantiomeric separation was 
obtained for 18 pairs of enantiomers including amphetamine, methamphetamine, MDMA and its 
metabolites HMA and HMMA, PMA, MDA and mephedrone. The method was applied in a one week 
monitoring study of a large wastewater treatment plant in the UK. Most target drugs were found at 
quantifiable concentrations in analysed samples. The results for several drugs such as cocaine and 
MDMA and their metabolites showed a clear trend of increased concentrations during weekend. 
Enantiomeric profiling revealed that amphetamine, methamphetamine and MDMA were found 
enriched with R-(-)-enantiomers, probably due to their stereoselective metabolism favouring S-(+)-
enantiomers. MDA was either enriched with R-(-)- or S-(+)-enantiomer indicating that its presence 
might be due to either abuse of racemic MDA or abuse of racemic MDMA. Non-racemic 
enantiomeric fractions were also observed in the case of HMMA and mephedrone suggesting 
enantioselective metabolism. To the authors’ knowledge, this is the first time chiral separation and 
wastewater profiling of mephedrone, PMA, MDMA and its metabolites HMA and HMMA is 
reported.  
Supplementary Data 
Supplementary material contains the following: 
Table S1 Selected analytes and their properties. 
Table S2 Studied mobile phase compositions with CHIRALPAK® CBH HPLC. 
Table S3 Studied mobile phase compositions with CHIROBIOTIC V. 
Table S4 Studied mobile phase compositions with CHIROBIOTIC T. 
Table S5 Validation parameters -instrumental precision. 
Table S6 Validation parameters- ion suppression. 
Figure S1 CBH column - enantiomeric resolution of studied analytes in a mobile phase containing 
acetonitrile as organic modifier (mobile phase composition: 1mM ammonium acetate/acetonitrile 
9:1). 
Figure S2 CBH column - enantiomeric resolution of studied analytes in a mobile phase containing 
isopropanol as organic modifier (mobile phase composition: (a) 1mM ammonium acetate/isopropanol 
9:1 and (b) 1mM ammonium acetate/isopropanol 9.5:0.5). 
Figure S3 CBH column - enantiomeric resolution of studied analytes in mobile phases containing: (a) 
1 mM ammonium acetate/methanol 9.5:0.5, (b) 1 mM ammonium acetate/methanol 9:1, (c) 2.5 mM 
ammonium acetate/methanol 9:1, (d) 5 mM ammonium acetate /methanol 9:1 and (e) 10 mM 
ammonium acetate /methanol 9:1. 
Figure S4 CBH column - Impact of different percentanges of modifiers on retention time of analytes. 
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Figure S5 Chirobiotic T column - overview of the separation for the targeted analytes 
Figure S6 Chirobiotic T column - separation of oxazepam and lorazepam. 
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Figure 1 Chromatograms of the quantification MRM transition for each investigated analyte of a 
spiked influent wastewater sample at a concentration of 500 ng L-1with CBH column 
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Table 1 Selected chiral drug biomarkers and their pharmacokinetic data 
Group Drug Metabolite Excretion Source of excretion (range) 
Stimulants Cocaine Cocaine 1.0-9.0%, 7.5% [25]; [26] 
Benzoylecgonine 32.5% (nasal) [27] 
Anhydroecgonine methyl ester (AEME) 0.7% [28] 
Cocaine and alcohol Cocaethylene  Drugbank [29], [28] 
Stimulants Amphetamine Amphetamine 30.0% in neutral condition of pH, up to 
74.0% in acidic and 1.0% in alkaline urines 
[25] 
Norephedrine 2.0% in neutral condition of pH [25] 
Stimulants Methamphetamine Methamphetamine 43.0% at pH range between 6 and 8, up to 
76.0% in acidic and 2.0% in alkaline urines 
[25] 
Amphetamine 4.0-7.0% at pH range between 6 and 8 [25] 
Stimulants Mephedrone Mephedrone Unknown  
Hallocinogens MDA MDA Unchanged (overdose case) [30] 
Hallocinogens MDMA MDMA 15.0% [31] 
MDA 1.5% [31] 
DHMA minor [32] 
HMMA 20.0% [31] 
HMA 1.0% [31] 
Hallocinogens MDEA MDEA 19.0% [25] 
MDA 28.0% [25] 
Opioids Diamorphine  Diamorphine  0.1% [33] 
Morphine derivative (O-6-MAM) 50.0-60.0% [33] 
Opioids Morphine  Morphine  10.0% [25] 
Morphine-3-glucuronide 75.0% [25] [34] 
Hydromorphone (not targeted) Trace [34] 
Normorphine Not found (Doris Clouet 2012) 
Dissociative 
agent 
Ketamine Ketamine 2.3% [25] 
Norketamine 1.6% [25] 
Stimulants Benzylpiperazine Benzylpiperazine 3.0-6.0% [35] 
Benzodiazepines Temazepam Temazepam 1.5%+73.0% as conjugated [25] 
Oxazepam 1.0%+5.8% as conjugated [25] 
Benzodiazepines Diazepam Diazepam Trace [25] 
Oxazepam gluc 33.0% [25] 
Temazepam 6.0% [25] 
Nordiazepam Trace (Steven B. Karch, 2007) 
Benzodiazepines Nitrazepam Nitrazepam trace, 1.0% (in the 7 day urine) [25] 
7-amino-nitrazepam 31.0% (in the 7 day urine) [25] 
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Benzodiazepines Oxazepam Oxazepam trace+61.0% as glucuronide [25] 
Benzodiazepines Lorazepam Lorazepam trace as unchanged + 75.0% lorazepam 
glucuronide 
[25] 
Population 
biomarkers 
Caffeine Caffeine 0.7-0.9%  
1,7-dimethylxanthine 14.0% [36] 
Population 
biomarkers 
Nicotine Nicotine 13.0%, 5.0% [5], [25] 
Cotinine 30.0%, 10.0% [5], [25] 
Population 
biomarkers 
Creatinine    
Opioids Codeine Codeine 10.0%, 32.0-46.0% as glucuronide Drugbank [29], [34] 
Morphine 5.0-13.0% [34] 
Opioids Oxycodone  Oxycodone  13.0-19.0%+7.0-29.0% as conjugated [25] 
Oxymorphone 13.0-14.0% as conjugated [25] 
Noroxycodone Trace [25] 
Opioids Hydrocodone Hydrocodone   
Hydromorphone (not targeted) 5.0% [34] 
Opioids Dihydrocodeine Dihydrocodeine 31.0%, 28.0% as conjugated [25] 
Dihydromorphine 8.4% as conjugated [25] 
Opioids Methadone Methadone 27.5 (5-50) [30] 
EDDP 3.0-25.0% [25] 
Antidepressants Venlafaxine Venlafaxine 5.0% [25] 
O-desmethylvenlafaxine 29.0-48.0% [25] 
Phosphodiesteras
e Type 5 Inhibitor 
Vardenafil Vardenafil <10.0% (Thomas L. Lemke, David A. 
Williams  2012)  
Precursors Ephedrine  Ephedrine  70.0-80.0% [25] 
Norephedrine  4.0% [25] 
Pseudoephedrine  Pseudoephedrine  88.0% [25] 
Stimulants PMA    
Opioids Tramadol  Tramadol  29.0% [25] 
O-desmethyltramadol 20.0% as free and conjugated [25] 
Z-drugs Zolpidem  Zolpidem  Nd [25] 
Antidepressants Amitriptyline Amitriptyline Trace Drugbank [29] 
Phosphodiesteras
e Type 5 Inhibitor 
Sildenafil Sildenafil 13.0% [25] 
Z-drugs Zopiclone Zopiclone 4.5 [25] 
Antidepressants Fluoxetine  Fluoxetine  2.5-5.0% [37] 
Norfluoxetine 10.0% [37] 
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Table 2 MRM transitions selected for studied analytes 
Compound CV/CEa MRM1 
(quantification) 
CV/CEa MRM2  
(confirmation) 
CV/C
Ea 
MRM3  
(confirmation) 
MRM1/MRM2 ratio ± SD MRM1/MR
M3 ratio ± 
SD 
Internal 
standard 
Cocaine 40/20 304.2 > 182.1 40/31 304.2 > 82.1 - - 2.8 ± 0.2 - Cocaine-D3 
Benzoylecgonine 38/19 290.2 > 168.1 38/30 290.2 > 105.1 - - 1.9 ± 0.2 - Benzoylecgonin
e-D8 
Cocaethylene 38/20 318.2 > 196.2 38/30 318.2 > 82.1 - - 1.9 ± 0.1 - Cocaethylene-
D3 
Anhydroecgonine methyl ester 
(AEME) 
39/23 182.1 > 118.0 39/21 182.1 > 122.1 - - 1.2 ± 0.1 - Cocaine-D3 
Amphetamine   18/16 136.16 > 91.1 18/8 136.16 > 
119.1 
- - 1.2 ± 0.1 -  Amphetamine-
D5 
Methamphetamine  24/19 150.2 > 91.1 24/10 150.2 > 119.1 - - 1.8 ± 0.1 - Methamphetami
ne-D5 
Benzylpiperazine (BZP) 35/20 177.1 > 91.1 35/15 177.1 > 85.1 - - 6.5 ± 0.6 - PCP-D5 
MDA  21/11 180.0 > 163.1 21/22 180.0 > 105.1 - - 2.6 ± 0.4 - MDA-D5 
MDMA 24/13 194.1 > 163.1 24/24 194.1 > 105.1 - - 2.1 ± 0.1 - MDMA-D5 
MDEA 28/13 208.1 > 163.1 28/27 208.1 > 105.1 - - 2.1 ± 0.2 - MDEA-D5 
HMA 6/14 182.1 > 165.0 6/24 182.1 > 105.0 6/18 182.1 > 133.0 1.8 ± 0.7 2.4 ±1.4 Amphetamine-
D5 
HMMA 16/12 196.1 > 165.0 16/26 196.1 > 105.0 16/22 196.1 > 133.0 3.1 ± 0.6 3.8 ±0.6 Methamphetami
ne-D5 
DHMA 6/12 182.1 > 151.0 6/18 182.1 > 123.0 6/24 182.1 > 105.0 2.8 ± 0.5 3.2 ±0.7 Amphetamine-
D5 
Mephedrone 10/12 178.1 > 160.1 10/22 178.1 > 145.0 10/22 178.1 > 119.0 1.6 ± 0.2 8.5 ±2.1  Mephedrone-
D3 
p-Methoxyamphetamine (PMA) 20/20 166.0 > 121.0 20/20 166.0 > 149.0 - - 12.5 ± 1.5 - MDA-D5 
Heroin 51/50 370.2 > 165.1 51/29 370.2 > 268.1 - - 1.5 ± 0.2 - Heroin-D9 
O-6-monoacetylmorphine (O-6-
MAM) 
52/39 328.1 > 165.1 52/26 328.1 > 211.1 - - 1.4 ± 0.3 - PCP-D5 
Codeine 49/25 300.2 > 215.1 49/57 300.2 > 152.1 - - 1.8 ± 0.1 - Codeine-D6 
Oxycodone 36/29 316.2 > 241.1 36/26 316.2 > 256.1 - - 1.4 ± 0.3 - Oxycodone-D6 
Noroxycodone 22/36 302.1 > 227.0 22/28 302.1 > 187.0 - - 5.5 ± 0.8  Oxycodone-D6 
Hydrocodone 24/34 300.1 > 199.0 24/46 300.1 > 171.0 - - 3.7 ± 0.2 - Hydrocodone-
D6 
Oxymorphone 40/19 302.1 > 284.1 40/28 302.1 > 227.1 - - 2.3 ± 0.2 - Oxycodone-D6 
Morphine 53/38 286.1 > 165.1 53/56 286.1 > 152.1 - - 1.2 ± 0.2 - Morphine-D6 
Normorphine 45/43 272.1 > 165.0 45/49 272.1 > 152.1 - - 1.3 ± 0.5 - Morphine-D6 
Dihydromorphine 28/42 288.2 > 185.0 28/32 288.2 > 213.0 28/42 288.2 > 231.0 2.9 ± 0.5 129.6 ±68.4 Morphine-D6 
Dihydrocodeine 53/33 302.1 > 199.1 53/60 302.1 > 128.1 - - 1.9 ± 0.2 - Codeine-D6 
Morphine-3β-D-glucuronide 56/44 462.3 > 286.1 56/80 462.3 > 165.0 56/56 462.3 > 201.1 4.7 ± 1.8 9.88 ±3.0 Morphine-3β-D-
glucuronide-D3 
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Methadone 31/15 310.2 > 265.1 31/28 310.2 > 105.1 - - 1.6 ± 0.5 - Methadone-D9 
EDDP 50/29 278.2 > 234.1 50/24 278.2 > 249.1 - - 2.3 ± 0.1 - EDDP-D3 
Tramadol 24/17 264.2 > 58.1 24/11 264.2 > 246.3 - - 102.1 ± 3.6 - Methamphetami
ne-D5 
O-desmethyl-tramadol 2/18 250.1 > 58.0 2/20 250.1 > 232.0 2/34 250.1 > 107.0 899.7 ± 14.7 1228.0 
±373.0 
Codeine-D6 
Temazepam 37/21 301.1 > 255.1 37/14 301.1 > 283.1 - - 2.2 ± 0.1 - Temazepam-D5 
Diazepam  54/27 285.0 > 154.1 54/31 285.0 > 193.1 - - 1.2 ± 0.1 - Diazepam-D5 
Nordiazepam  51/29 271.1 > 140.1 51/29 271.1 > 165.0 - - 2.0 ± 0.1 - Nordiazepam-
D5 
Nitrazepam 44/24 282.1 > 236.1 44/37 282.1 > 180.1 - - 2.5 ± 0.3 - Nitrazepam-D5 
7-aminonitrazepam 48/25 252.1 > 121.1 48/40 252.1 > 94.1 - - 5.7 ± 0.9 - Nitrazepam-D5 
Oxazepam 38/21 287.1 > 241.1 38/15 287.1 > 269.0 - - 1.3 ± 0. - Oxazepam-D4 
Lorazepam 30/20 321.0 > 275.1 30/33 321.0 > 229.1 - - 3.3 ± 1.4 - Lorazepam-D4 
Zopiclone 22/18 389.1 > 245.0 22/42 389.1 > 217.0 - -   Zopiclone-D4 
Zolpidem 8/36 308.2 > 235.2 8/36 308.2 > 263.0 - - 1.7 ± 0.5  Cocaine-D3 
Amitriptyline 37/26 278.2 > 91.1 37/18 278.2 > 233.2 - - 1.8 ± 0.2 - EDDP-D3 
Fluoxetine 25/8 310.3 > 148.1 - - - - - - MDMA-D5 
Norfluoxetine 17/7 296.2 > 134.1 - - - - - - MDMA-D5 
Venlafaxine 27/12 278.2 > 58.1 27/12 278.2 > 260.1 27/32 278.2 > 121.0 2.7 ± 0.2 4.5 ±0.7 Methamphetami
ne-D5 
Desmethylvenlafaxine 25/24 264.0 > 58.1 25/24 264.0 > 107.1 25/20 264.0 > 246.3 12.7 ± 1.8 66.4 ±5.9 Methamphetami
ne-D5 
Ketamine  31/27 238.1 > 125.0 31/15 238.1 > 220.1 - - 3.3 ± 0.5 - Ketamine-D4 
Norketamine  23/27 224.0 > 125.0 23/12 224.0 > 207.1 - - 1.1 ± 0.1 - Norketamine-
D4 
Sildenafil 60/28 475.3 > 100.2 68/50 475.3 > 283.2 68/36 475.3 > 311.2 28.6 ± 8.6  17.3 ±4.0 PCP-D5 
Vardenafil 74/68 489.3 > 151.0 74/48 489.3 > 321.1 - - 7.2 ± 3.0 - Methadone-D9 
Ephedrine  23/12 166.1 > 148.1 23/21 166.1 > 133.0 - - 7.4 ± 0.8 - 1S, 2R-(+)-
ephedrine-D3 
Pseudoephedrine 23/12 166.1 > 148.1 23/21 166.1 > 133.0 - - 6.9 ± 0.6 - 1S, 2R-(+)-
ephedrine-D3 
Norephedrine 23/10 152.1 > 134.1 23/16 152.1 > 117.1 - - 3.1 ± 0.4 - 1S, 2R-(+)-
ephedrine-D3 
Caffeine 38/15 195.1 > 138.0 38/23 195.1 > 110.0 - - 2.5 ± 0.3 - Cotinine-D3 
1,7-dimethylxanthine 54/21 181.0 > 124.1 - - -  
 
- - - Cotinine-D3 
Nicotine 37/20 163.1 > 130.0 37/24 163.1 > 117.0 - - 1.4 ± 0.1 - Cotinine-D3 
Cotinine 34/21 177.1 > 80.0 34/22 177.1 > 98.1 - - 2.8 ± 0.2 - Cotinine-D3 
Creatinine 31/11 114.0 > 86.1 31/16 114.0 > 72.1 - - 21.9 ± 4.2 - Cotinine-D3 
aCV, cone voltage (V); CE, collision energy (eV) 
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Table 3 MRM transitions selected for internal standards used in the method 
Internal Standards CV/CEa MRM1 (quantification) 
Cocaine-D3 40/20 307.2 > 185.1 
Benzoylecgonine-D8 38/19 298.2 > 171.1 
Cocaethylene-D3 42/20 321.2 > 199.1 
Ecgonine Methyl ester-D3 44/22 203.2 > 185.2 
Amphetamine-D5 22/16 141.0 > 92.9 
Methamphetamine-D5 28/12 155.1 > 121.0 
PCP-D5 18/14 249.2 > 164.1 
Mephedrone-D3 30/22 181.1 > 163.1 
MDA-D5 21/11 185.1 > 168.1 
MDMA-D5 26/13 199.1 > 165.1 
MDEA-D5 28/13 213.1 > 163.0 
Cotinine-D3 44/24 180.1 > 80.0 
EDDP-D3 50/29 281.2 > 234.1 
Heroin-D9 51/50 379.2 > 165.8 
Codeine-D6 52/28 306.2 > 218.1 
Oxycodone-D6 36/29 322.2 > 247.1 
Hydrocodone-D6 64/32 306.2 > 202.0 
Morphine-D6 53/38 292.2 > 153.1 
Morphine-3β-D-
glucuronide-D3 
52/36 465.2 > 289.1 
Methadone-D9 31/15 319.3 > 268.2 
Temazepam-D5 37/21 306.7 > 260.1 
Diazepam-D5 54/27 290.1 > 154.1 
Nordiazepam-D5 48/36 276.1 > 140.1 
Nitrazepam-D5 52/42 287.1 > 185.0  
Oxazepam-D4 38/21 292.0 > 246.0 
Lorazepam-D4 25/29 325.0 > 279.2 
Zopiclone-D4 24/16 393.1 > 245.0 
Ketamine-D4 31/27 242.1 > 129.1 
Norketamine-D4 32/28 228.1 > 128.9 
1S,2R-(+)-Ephedrine-D3 23/18 169.2 > 151.0 
aCV, cone voltage (V); CE, collision energy (eV) 
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Table 4 SPE recovery for the studied analytes 
Analyte SPE relative recovery % (n=3) 
 25 ng/L* 250 ng/L* 2500 ng/L* 
Cocaine 100.0 ± 1.9 91.0 ± 0.7 85.0 ± 1.7 
Benzoylecgonine 76.0 ± 1.4 79.0 ± 1.8 98.0 ± 3.9 
Cocaethylene 102.0 ± 2.6 92.0 ± 0.2 94.0 ± 1.4 
R-(-)-Amphetamine 101.0  ± 6.6 76.0  ± 1.6 82.0 ± 4.7 
S-(+)-Amphetamine 81.0  ± 10.6 99.0  ± 2.0 82.0 ± 4.2 
R-(-)-Methamphetamine 91.0 ± 4.4 113.0 ± 0.7 82.0 ± 5.0 
S-(+)-Methamphetamine 84.0 ± 1.9 86.0 ± 1.2 84.0 ± 7.1 
E1-Mephedrone 109.0 ± 3.2 99.0 ± 4.8 80.0 ± 7.0 
E2-Mephedrone 99.0 ± 8.5 99.0 ± 4.3 87.0 ± 11.5 
R-(-)-MDA 93.0 ± 6.2 94.0 ± 4.2 81.0 ± 1.0 
S-(+)-MDA 110.0 ± 8.5 99.0 ± 1.5 91.0 ± 1.5 
R-(-)-MDMA 91.0 ± 3.7 81.0 ± 7.8 89.0 ± 4.3 
S-(+)-MDMA 93.0 ± 1.7 100.0 ± 0.7 84.0 ± 1.9 
E1-MDEA 102.0 ± 2.0 95.0 ± 8.6 91.0 ± 5.9 
E2-MDEA 99.0 ± 1.8 92.0 ± 1.9 93.0 ± 13.4 
Heroin 86.0 ± 9.4 80.0 ± 5.6 75.0 ± 2.4 
O-6-monoacetylmorphine 108.0 ± 2.3 120.0 ± 1.4 114.0 ± 1.0 
Morphine 98.0 ± 15.2 92.0 ± 1.3 112.0 ± 3.2 
Morphine-3β-D-glucuronide 99.0 ± 0.5 121.0 ± 2.5 109.0 ± 5.3 
Ketamine 127.0 ± 2.5 100.0 ± 5.7 85.0 ± 6.2 
Benzylpiperazine 112.0 ± 5.3 96.0 ± 13.1 100.0 ± 4.9 
Temazepam 117.0 ± 4.1 117.0 ± 3.0 99.0 ± 4.7 
Diazepam 93.0 ± 3.9 115.0 ± 0.3 95.0 ± 4.9 
Nordiazepam 108.0 ± 9.0 
108.0 ± 
11.2 96.0 ± 4.7 
Nitrazepam 89.0 ± 3.1 91.0 ± 2.7 89.0 ± 1.5 
Oxazepam 92.0 ± 2.7 117.0 ± 1.4 92.0 ± 1.6 
7-amino-nitrazepam 83.0 ± 6.4 85.0 ± 0.4 80.0 ± 4.1 
Lorazepam 98.0 ± 14.4 108.0 ± 3.4 86.0 ± 3.0 
Anhydroecgonine methyl ester 80.0 ± 5.3 102.0 ± 0.1 86.0 ± 0.4 
E1-HMA 97.0 ± 8.7 114.0 ± 0.3 106.0 ± 16.4 
E2-HMA 106.0 ± 4.6 107.0 ± 2.9 120.0 ± 11.5 
E1-HMMA 84.0 ± 8.8 85.0 ± 9.4 100.0 ± 3.3 
E2-HMMA 108.0 ± 7.5 105.0 ± 2.4 118.0 ± 1.7 
DHMA 108 ± 11.9 112 ± 2.4 111 ± 2.8 
Caffeine 80.0 ± 2.5 84.0 ± 2.7 80.0 ± 1.5 
1,7-dimethylxanthine 104.0 ± 0.5 100.0 ± 1.3 106.0 ± 2.4 
Nicotine 97.0 ± 2.5 81.0 ± 6.2 120.0 ± 9.5 
Cotinine 105.0 ± 2.8 93.0 ± 6.1 89.0 ± 3.5 
Creatinine 80.0 ± 4.6 94.0 ± 9.5 109.0 ± 13.3 
Codeine 95.0 ± 6.7 108.0 ± 3.1 107.0 ± 2.1 
Oxycodone 84.0 ± 2.1 91.0 ± 3.8 99.0 ± 3.3 
Noroxycodone 93.0 ± 11.3 80.0 ± 2.8 90.0 ± 3.2 
Hydrocodone 84.0 ± 3.1 104.0 ± 8.9 101.0 ± 10.6 
Oxymorphone 94.0 ± 5.7 87.0 ± 7.7 89.0 ± 1.2 
Dihydrocodeine 98.0 ± 7.3 104.0 ± 2.9 89.0 ± 3.8 
Methadone 95.0 ± 0.9 116.0 ± 0.5 89.0 ± 1.4 
EDDP 90.0 ± 6.5 97.0 ± 3.0 90.0 ± 1.1 
E1-Venlafaxine 83.0 ± 0.6 105.0 ± 6.3 91.0 ± 0.4 
E2-Venlafaxine 91.0 ± 5.8 104.0 ± 5.4 90.0 ± 0.7 
Vardenafil 120.0 ± 0.5 
115.0 ± 
11.0 100.0 ± 8.8 
E1-Norephedrine 112.0 ± 2.8 117.0 ± 1.1 108.0 ± 1.5 
E2-Norephedrine 115.0 ± 5.9 95.0 ± 2.1 83.0 ± 1.4 
E1-PMA 110.0 ± 8.5 94.0 ± 2.4 80.0 ± 0.7 
E2-PMA 113.0 ± 3.5 118.0 ± 5.9 91.0 ± 0.4 
Normorphine 80.0 ± 8.4 80.0 ± 11.9 111.0 ± 4.0 
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Dihydromorphine 106.0 ± 0.5 80.0 ± 2.0 80.0 ± 4.5 
D1-Tramadol 109.0 ± 6.0 111.0 ± 7.2 96.0 ± 10.0 
D2-Tramadol 90.0 ± 7.8 81.0 ± 2.7 80.0 ± 1.1 
O-Demethyltramadol 80.0 ± 6.4 118.0 ± 4.4 80.0 ± 3.3 
Zolpidem 101.0 ± 0.8 96.0 ± 14.0 115.0 ± 1.7 
Amitriptyline 81.0 ± 0.2 82.0 ± 2.9 92.0 ± 2.7 
Norketamine 89.0 ± 8.2 116.0 ± 2.6 102.0 ± 2.2 
Sildenafil 115.0 ± 0.7 105.0 ± 8.5 96.0 ± 9.0 
(+)-Ephedrine 81.0 ± 9.0 82.0 ± 2.6 91.0 ± 2.1 
(-)-Ephedrine and (-)-Ψephedrine 112.0 ± 0.6 87.0 ± 2.5 113.0 ± 9.6 
(+)-Ψephedrine 104.0 ± 10.6 83.0 ± 0.3 81.0 ± 1.0 
Desmethylvenlafaxine-E1 91.0 ± 9.8 
113.0 ± 
14.2 98.0 ± 6.5 
Desmethylvenlafaxine-E2 82.0 ± 1.1 92.0 ± 4.1 99.0 ± 10.7 
E1-Zopiclone 80.0 ± 2.0 82.0 ± 0.7 81.0 ± 3.7 
E2-Zopiclone 80.0 ± 1.2 80.0 ± 6.7 83.0 ± 4.6 
S-(+)-Fluoxetine 100.0 ± 5.5 81.0 ± 3.8 100.0 ± 0.7 
R-(-)-Fluoxetine 97.0 ± 16.6 91.0 ± 5.5 101.0 ± 7.1 
E1-Norfluoxetine 87.0 ± 1.7 80.0 ± 4.6 87.0 ± 5.3 
E2-Norfluoxetine 80.0 ± 0.4 81.0 ± 1.7 84.0 ± 2.6 
*- the following concentrations were used: 50, 500 and 5000 ng L-1 in the case of compounds that were not 
enantioseparated
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Table 5 Validation parameters - retention time, relative retention time, linearity range, correlation coefficient obtained from calibration curve and 
instrumental and method limits of detection and instrumental and method limits of quantification 
Compound Rt 
(min) 
Rel. Rt 
  
Sample diluent WWTP influent 
Linearity range 
(µg/L) 
R2 IDLS/N (µg/L) IQLS/N (µg/L) MDL (µg/L) MQL (µg/L) 
Cocaine 15.7 ±0.4 0.3 0.010-1000 0.9997 0.01 0.05 0.0001 0.0003 
Benzoylecgonine 3.1 ±0.0 0.0 0.005-1000 0.9992 0.01 0.02 0.0001 0.0001 
Cocaethylene 16.0 ±0.7 0.3 0.100-1000 0.9996 0.10 0.25 0.0005 0.0013 
R-(-)-Amphetamine 15.5 ±0.3 0.1 0.125-500 0.9987 0.12 0.50 0.0008 0.0029 
S-(+)-Amphetamine 22.6 ±0.4 0.2 0.125-500 0.9988 0.12 0.50 0.0008 0.0029 
R-(-)-Methamphetamine 14.5 ±0.4 0.3 0.050-500 0.9989 0.05 0.12 0.0003 0.0006 
S-(+)-Methamphetamine 16.5 ±0.4 0.3 0.050-500 0.9994 0.05 0.12 0.0003 0.0007 
E1-Mephedrone 16.5 ±0.4 0.3 0.250-500 0.9990 0.25 0.50 0.0013 0.0026 
E2-Mephedrone 21.0 ±0.5 0.2 0.250-500 0.9993 0.25 0.50 0.0007 0.0026 
R-(-)-MDA 28.1 ±0.5 0.2 0.500-500 0.9991 0.50 2.50 0.0028 0.0140 
S-(+)-MDA 47.4 ±0.8 0.4 0.500-500 0.9980 0.50 2.50 0.0025 0.0124 
R-(-)-MDMA 21.9 ±0.5 0.2 0.050-500 0.9992 0.05 0.25 0.0003 0.0014 
S-(+)-MDMA 32.9 ±0.5 0.1 0.050-500 0.9994 0.05 0.25 0.0003 0.0013 
E1-MDEA 19.0 ±0.5 1.8 0.125-500 0.9994 0.12 0.25 0.0006 0.0013 
E2-MDEA 21.0 ±0.5 0.2 0.125-500 0.9995 0.12 0.25 0.0007 0.0013 
Heroin 22.5 ±0.4 0.5 1.000-1000 0.9946 1.00 5.00 0.0062 0.0312 
O-6-monoacetylmorphine 24.1 ±0.7 1.1 0.250-1000 0.9987 0.25 1.00 0.0011 0.0044 
Morphine 17.4 ±0.8 0.5 0.250-1000 0.9955 0.25 0.50 0.0012 0.0025 
Morphine-3β-D-
glucuronide 
3.3 ±0.0 6.5 0.500-1000 0.9983 0.50 5.00 0.0023 0.0228 
Ketamine 11.6 ±0.2 0.3 0.100-1000 0.9994 0.10 0.25 0.0005 0.0012 
Benzylpiperazine 21.3 ±0.4 1.6 0.500-1000 0.9957 0.50 1.00 0.0024 0.0048 
Temazepam 5.2 ±0.2 1.2 0.250-1000 0.9972 0.25 0.50 0.0011 0.0022 
Diazepam 6.0 ±0.3 0.6 0.250-1000 0.9974 0.25 0.50 0.0012 0.0024 
Nordiazepam 8.9 ±0.2 0.5 0.250-1000 0.9985 0.25 0.50 0.0012 0.0024 
Nitrazepam 7.3 ±0.0 1.4 0.250-1000 0.9984 0.25 0.50 0.0014 0.0027 
Oxazepam 7.0 ±0.2 4.8 0.500-1000 0.9971 0.50 1.00 0.0025 0.0049 
7-amino-nitrazepam 5.3 ±0.1 0.6 0.250-1000 0.9923 0.25 0.50 0.0015 0.0030 
Lorazepam 6.8 ±0.1 1.4 1.000-800 0.9900 1.00 5.00 0.0051 0.0256 
Anhydroecgonine methyl 
ester 
12.4 ±0.2 0.5 0.500-1000 0.9971 0.50 1.00 0.0028 0.0056 
E1-HMA 17.7 ±0.4 0.4 2.500-500 0.9900 2.50 5.00 0.0118 0.0236 
E2-HMA 34.3 ±0.5 0.8 2.500-500 0.9903 2.50 5.00 0.0113 0.0225 
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E1-HMMA 15.9 ±0.4 2.5 0.250-500 0.9982 0.25 0.50 0.0014 0.0028 
E2-HMMA 18.6 ±0.5 2.5 0.250-500 0.9974 0.25 0.50 0.0011 0.0022 
DHMA 12.5 ±0.2 4.1 1.000-1000 0.9959 1.00 5.00 0.0045 0.0226 
Caffeine 6.1 ±0.0 0.8 0.250-1000 0.9981 0.25 0.50 0.0047 0.0259 
1,7-Dimethylxanthine 6.4 ±0.1 0.8 1.000-1000 0.9983 1.00 5.00 0.0048 0.0241 
Nicotine 12.5 ±0.1 2.6 0.250-1000 0.9964 0.25 0.50 0.0013 0.0025 
Cotinine 3.4 ±0.0 0.5 0.010-1000 0.9988 0.01 0.02 0.0001 0.0001 
Creatinine 3.0 ±0.0 2.0 1.000-1000 0.9943 1.00 5.00 0.0053 0.0265 
Codeine 15.8 ±0.4 0.3 0.500-1000 0.9980 0.50 1.00 0.0024 0.0048 
Oxycodone 16.1 ±0.7 0.3 0.250-1000 0.9977 0.25 1.00 0.0014 0.0054 
Noroxycodone 20.7 ±0.3 0.6 1.000-1000 0.9991 1.00 5.00 0.0057 0.0285 
Hydrocodone 19.2 ±1.1 0.4 1.000-1000 0.9987 1.00 5.00 0.0052 0.0259 
Oxymorphone 18.7 ±0.5 0.3 1.000-1000 0.9976 1.00 5.00 0.0056 0.0278 
Dihydrocodeine 14.0 ±0.5 0.6 0.500-1.000 0.9985 0.50 1.00 0.0026 0.0051 
Methadone 21.3 ±1.3 0.3 0.250-1000 0.9992 0.25 0.50 0.0012 0.0025 
EDDP 19.7 ±0.5 0.2 0.025-1000 0.9993 0.02 0.10 0.0001 0.0005 
E1-Venlafaxine 12.5 ±0.5 0.6 0.125-500 0.9980 0.12 0.25 0.0007 0.0013 
E2-Venlafaxine 15.6 ±0.5 2.9 0.125-500 0.9971 0.12 0.25 0.0007 0.0013 
Vardenafil 24.7 ±1.3 2.8 1.000-1000 0.9911 1.00 5.00 0.0045 0.0223 
E1-Norephedrine 13.6 ±0.3 0.4 0.125-500 0.9981 0.12 0.25 0.0006 0.0011 
E2-Norephedrine 15.1 ±0.4 2.2 0.125-500 0.9983 0.12 0.25 0.0006 0.0012 
E1-PMA 21.3 ±0.5 0.5 0.125-500 0.9964 0.12 0.25 0.0007 0.0013 
E2-PMA 36. 8 ±0.4 1.4 0.125-500 0.9994 0.12 0.25 0.0006 0.0011 
Normorphine 20.0 ±0.6 0.8 1.000-800 0.9905 1.00 5.00 0.0055 0.0276 
Dihydromorphine 15.1 ±0.5 0.5 1.000-800 0.9915 1.00 5.00 0.0056 0.0282 
D1-Tramadol 12.6 ±0.4 0.6 0.500-500 0.9985 0.50 1.00 0.0024 0.0047 
D2-Tramadol 13.7 ±0.5 0.7 0.500-500 0.9989 0.50 1.00 0.0029 0.0059 
O-Demethyltramadol 13.5 ±0.4 0.8 0.500-1000 0.9921 0.50 1.00 0.0027 0.0053 
Zolpidem 15.1 ±0.6 2.3 0.025-1000 0.9924 0.02 1.00 0.0001 0.0047 
Amitriptyline 55.3±3.1 2.9 5.000-1000 0.9950 5.00 10.00 0.0294 0.0588 
Norketamine 8.5 ±0.3 0.6 0.500-1000 0.9986 0.50 1.00 0.0024 0.0048 
Sildenafil 17.7 ±1.0 3.8 1.000-1000 0.9911 1.00 5.00 0.0047 0.0237 
(+)-Ephedrine 12.3 ±0.3 0.6 1.000-500 0.9974 1.00 5.00 0.0059 0.0295 
(-)-Ephedrine and (-)-
Ψephedrine 
13.4 ±0. 0.5 0.500-1000 0.9975 0.50 1.00 0.0024 0.0048 
(+)-Ψephedrine 32.94 ±0.8 1.9 1.000-500 0.9903 1.00 5.00 0.0056 0.0280 
Desmethylvenlafaxine-E1 15.8 ±0.4 0.7 5.000-500 0.9941 5.000 10.000 0.0249 0.0497 
Desmethylvenlafaxine-E2 17.2 ±0.4 0.6 5.000-500 0.9973 5.000 10.000 0.0275 0.0550 
E1-Zopiclone 32.7 ±0.3 4.6 10.000-500 0.9903 10.000 50.000 0.0285 0.3125 
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E2-Zopiclone 59.8 ±0.4 5.2 10.000-500 0.9909 10.000 50.000 0.0326 0.3208 
S-(+)-Fluoxetine 43.2 ±1.8 3.1 10.000-500 0.9915 10.000 50.000 0.0533 0.2664 
R-(-)-Fluoxetine 57.2 ±2.1 3.3 10.000-500 0.9907 10.000 50.000 0.0517 0.2588 
E1-Norfluoxetine 81.3 ±6.0 14.4 10.000-500 0.9916 10.000 50.000 0.0589 0.2945 
E2-Norfluoxetine 87.8 ±3.5 12.9 10.000-500 0.9921 10.000 50.000 0.0612 0.3061 
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Table 6 Validation parameters - enantiomeric fraction (EF) and enantiomeric resolution (Rs) 
of compounds, which enantiomers were separated under studied conditions.  
 Structure Rs EF (n=9) 
10 µg/L 100 µg/L 1000 µg/L 
Amphetamine 
 
1.2±0.1 0.47±0.01 0.49±0.02 0.48±0.01 
Methamphetamine 
 
1.0±0.0 0.50±0.00 0.49±0.00 0.49±0.00 
Mephedrone 
 
1.4±0.1 0.50±0.01 0.50±0.00 0.48±0.01 
MDA 
 
1.8±0.2 0.47±0.01 0.48±0.01 0.50±0.00 
MDMA 
 
1.2±0.1 0.51±0.00 0.50±0.00 0.51±0.00 
MDEA 
 
0.8±0.3 0.50±0.01 0.51±0.01 0.50±0.01 
HMA 
 
2.7±0.3 0.54±0.08 0.47±0.00 0.49±0.05 
HMMA 
 
0.8±0.1 0.48±0.01 0.43±0.01 0.40±0.00 
Tramadol 
 
0.9±0.0 0.46±0.01 0.46±0.02 0.49±0.03 
Fluoxetine 
 
0.6±0.2 0.51±0.03 0.50±0.02 0.51±0.04 
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Norfluoxetine 
 
1.9±0.10 0.50±0.08 0.47±0.05 0.50±0.07 
Venlafaxine 
 
 
 
1.0±0.1 0.50±0.04 0.49±0.01 0.50±0.01 
(+)-Ephedrine 
 
0.9±0.1 0.40±0.03 0.50±0.1 0.49±0.16 
(+)-
Pseudoephedrine 
2.2±0.2 0.52±0.01 0.45±0.03 0.42±0.02 
Norephedrine 
 
0.9±0.1 0.50±0.04 0.46±0.01 0.47±0.00 
Zopiclone 
 
3.1±0.2 0.43±0.02 0.47±0.01 0.48±0.02 
Desmethylvenlafaxi
ne 
 
0.9±0.1 0.42±0.04 0.43±0.03 0.40±0.03 
PMA 
 
2.7±0.2 0.48±0.02 0.47±0.01 0.41±0.00 
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Table 7 Validation parameters - method precision 
Analytes Intra-day RSD% (n=4) Inter-day RSD% (n=3) 
 25 
ng/L** 
25 
ng/L 
25 
ng/L 
250 
ng/L 
250 
ng/L 
250 
ng/L 
2500 
ng/L 
2500 
ng/L 
2500 
ng/L 
25 
ng/L 
250 
ng/L 
2500 
ng/L 
 D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3    
Cocaine 6.5 2.7 5.2 0.5 4.8 3.4 4.7 1.9 1.5 4.8 2.9 2.7 
Benzoylecgonine 2.3 7.5 10.2 5.3 4.6 6.6 14.4 2.5 4.9 6.6 5.5 7.3 
Cocaethylene 3.5 5.1 5.4 6.4 3.8 3.8 6.1 2.0 4.3 4.7 4.7 4.2 
R-(-)-Amphetamine 3.3 2.5 4.6 5.2 14.7 10.8 6.2 3.9 6.2 3.5 10.2 5.4 
S-(+)-
Amphetamine 
3.1 4.3 12.6 1.4 6.5 4.7 3.8 7.0 7.3 6.7 4.2 6.0 
R-(-)-
Methamphetamine 
8.9 6.7 9.3 3.4 7.0 8.3 4.8 5.2 5.4 8.3 6.2 5.1 
S-(+)-
Methamphetamine 
6.8 3.6 15.4 1.2 5.5 4.0 2.7 2.9 4.2 8.6 3.6 3.3 
E1-Mephedrone 9.8 13.7 14.1 3.6 6.8 14.6 3.7 10.0 5.6 12.5 8.3 6.4 
E2-Mephedrone 10.7 12.0 4.6 5.2 12.9 8.4 9.2 3.7 2.8 9.1 8.8 5.2 
R-(-)-MDA 1.7 6.6 9.7 3.0 3.4 5.7 0.1 7.7 1.1 6.0 4.0 3.0 
S-(+)-MDA 4.4 3.8 7.8 2.6 6.7 5.3 7.2 3.7 4.5 5.3 4.9 5.1 
R-(-)-MDMA 7.0 1.8 4.0 5.8 4.6 3.9 3.4 1.5 6.5 4.3 4.8 3.8 
S-(+)-MDMA 1.0 1.9 6.9 0.6 3.1 2.9 1.2 2.8 0.7 3.3 2.2 1.6 
E1-MDEA 6.9 6.2 3.0 5.1 8.5 7.8 4.7 2.2 4.3 5.4 7.1 3.7 
E2-MDEA 6.0 6.3 2.8 1.4 9.2 4.9 8.3 1.4 1.7 5.0 5.2 3.8 
Heroin 17.3 12.0 1.1 4.4 6.8 6.4 10.5 5.2 12.2 10.1 5.9 9.3 
O-6-
monoacetylmorphi
ne 
3.3 6.9 12.1 4.2 6.6 5.7 5.8 3.8 6.3 7.4 5.5 5.3 
Morphine 17.8 0.8 0.8 8.8 4.5 6.7 6.7 7.2 14.2 6.5 6.7 9.4 
Morphine-3β-D-
glucuronide 
18.2 3.7 23.2 27.1 10.4 4.8 18.6 19.4 4.2 15.0 14.1 14.1 
Ketamine 8.3 2.2 3.9 2.0 5.2 3.9 1.9 1.6 2.0 4.8 3.7 1.8 
Benzylpiperazine 4.4 1.0 9.4 4.3 7.1 5.2 1.9 4.8 2.1 5.0 5.5 2.9 
Temazepam 25.9 16.4 5.5 6.7 8.7 8.5 4.1 3.8 2.7 15.9 8.0 3.5 
Diazepam 2.1 5.4 5.8 5.0 9.5 8.4 1.8 3.9 2.7 4.4 7.6 2.8 
Nordiazepam 3.1 19.8 7.0 4.7 5.5 5.6 15.7 5.1 6.1 9.9 5.3 9.0 
Nitrazepam 9.0 1.2 18.7 9.2 4.5 5.2 6.2 5.1 1.9 9.6 6.3 4.4 
Oxazepam 13.7 10.0 10.7 3.9 8.3 5.6 3.4 5.3 7.9 11.4 5.9 5.5 
7-amino-
nitrazepam 
0.0 4.5 5.0 3.4 5.8 2.0 0.0 2.1 5.2 3.2 3.7 2.4 
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Lorazepam 4.4 10.6 6.7 9.9 3.9 2.4 3.9 6.8 3.3 7.2 5.4 4.7 
Anhydroecgonine 
methyl ester 
5.3 9.3 3.6 1.4 5.6 5.7 3.0 3.2 1.0 6.1 4.2 2.4 
E1-HMA 4.4 5.1 1.6 7.6 1.1 4.4 6.4 6.0 5.9 3.7 4.4 6.1 
E2-HMA 5.2 4.8 12.6 3.8 2.0 5.0 7.0 6.5 6.0 7.5 3.6 6.5 
E1-HMMA 7.4 7.6 7.5 2.8 3.8 6.0 4.1 2.7 0.3 7.5 4.2 2.4 
E2-HMMA 4.7 6.4 3.6 2.1 2.1 6.2 2.9 3.1 3.6 4.9 3.5 3.2 
DHMA 8.9 9.1 1.2 6.1 2.5 9.0 3.2 6.9 4.6 6.4 5.9 4.9 
Caffeine 2.2 5.6 2.2 5.1 7.3 3.8 9.5 0.9 1.9 3.3 5.4 4.1 
1,7-
Dimethylxanthine 
6.0 4.0 5.7 4.5 0.0 4.7 2.7 3.5 5.8 5.2 3.1 4.0 
(-)-Nicotine 3.7 4.0 8.5 6.6 1.8 4.0 1.6 5.5 5.4 5.4 4.1 4.1 
Cotinine 3.0 8.1 6.8 4.4 4.0 4.8 3.2 6.1 4.7 6.0 4.4 4.7 
Creatinine 18.3 1.0 9.7 2.7 14.9 8.8 0.7 7.6 4.4 9.6 8.8 4.2 
Codeine 2.9 4.5 4.9 2.1 5.7 7.8 6.4 2.7 9.0 4.1 5.2 6.0 
Oxycodone 10.5 4.2 16.8 2.3 4.4 8.6 3.3 7.0 7.6 10.5 5.1 6.0 
Noroxycodone 19.3 9.2 14.1 2.6 9.3 7.4 4.9 8.3 5.4 14.2 6.4 6.2 
Hydrocodone 4.7 1.1 1.9 3.8 9.2 7.1 1.4 5.5 7.8 2.6 6.7 4.9 
Oxymorphone 5.3 2.1 6.7 3.7 0.6 3.5 4.9 3.5 6.7 4.7 2.6 5.0 
Dihydrocodeine 0.3 7.6 4.7 1.0 7.0 1.7 5.6 3.9 3.7 4.2 3.2 4.4 
Methadone 7.8 0.0 7.3 2.1 4.4 6.5 5.9 2.8 5.7 5.0 4.4 4.8 
EDDP 3.1 5.3 6.2 3.9 9.4 5.3 5.1 1.1 2.9 4.9 6.2 3.0 
E1-Venlafaxine 9.1 1.5 5.7 5.5 5.2 7.5 5.3 7.1 5.6 5.4 6.1 6.0 
E2-Venlafaxine 0.0 4.8 3.1 4.9 1.4 7.6 1.5 4.0 5.2 2.6 4.6 3.6 
Vardenafil 9.4 11.0 10.6 5.6 9.2 13.0 14.6 9.0 5.2 10.3 9.3 9.6 
E1-Norephedrine 7.3 3.8 1.3 2.8 3.0 7.3 4.4 3.0 7.4 4.1 4.3 5.0 
E2-Norephedrine 5.7 4.6 6.3 3.1 3.9 6.1 2.2 2.1 3.5 5.5 4.3 2.6 
E1-PMA 7.7 4.8 8.3 1.4 4.4 3.7 3.8 4.3 5.3 6.9 3.2 4.5 
E2-PMA 6.2 8.8 11.6 7.8 4.6 6.6 1.7 3.9 2.9 8.9 6.3 2.8 
Normorphine 11.4 2.9 4.6 2.7 12.6 5.5 12.0 3.6 7.8 6.3 6.9 7.8 
Dihydromorphine 1.5 13.4 4.1 10.1 14.9 1.4 9.8 2.6 11.3 6.3 8.8 7.9 
D1-Tramadol 4.9 7.0 6.6 6.1 5.7 3.9 6.5 1.7 0.5 6.2 5.3 2.9 
D2-Tramadol 6.2 9.7 6.1 4.2 3.2 4.0 2.5 3.7 2.5 7.3 3.8 2.9 
O-
Desmethyltramadol 
4.8 8.7 0.0 15.7 16.0 4.6 12.2 16.2 11.5 4.5 12.1 13.3 
Zolpidem 18.2 7.0 0.6 5.5 3.4 4.8 0.6 9.1 6.9 8.6 4.5 5.5 
Amitriptyline 8.0 7.3 1.1 10.9 7.3 8.7 2.7 6.7 0.1 5.5 9.0 3.1 
Norketamine 9.6 7.6 11.2 7.7 8.0 8.3 6.5 5.8 3.6 9.5 8.0 5.3 
Sildenafil 20.1 5.9 20.8 1.2 13.3 10.1 5.6 3.5 6.8 15.6 8.2 5.3 
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(+)-Ephedrine 5.3 16.5 9.8 5.0 4.5 6.6 7.2 2.8 3.3 10.5 5.4 4.4 
(-)-Ephedrine and (-
)-Ψephedrine 
8.3 14.8 5.2 1.8 0.8 5.4 5.7 1.0 3.3 9.4 2.7 3.3 
(+)-Ψephedrine 2.8 2.5 6.2 5.8 1.3 9.4 2.9 2.0 1.7 3.8 5.5 2.2 
Desmethylvenlafax
ine-E1 
8.7 7.4 2.3 8.4 3.7 9.5 2.7 5.0 3.7 6.2 7.2 3.8 
Desmethylvenlafax
ine-E2 
6.4 8.7 7.4 3.8 2.8 5.3 2.3 4.9 8.2 7.5 4.0 5.1 
E1-Zopiclone 20.0 17.8 19.5 14.5 13.2 19.2 12.6 7.9 5.6 19.1 15.6 8.7 
E2-Zopiclone 18.7 18.2 20.4 17.6 14.8 6.9 11.4 5.8 9.8 19.2 13.1 9.0 
S-(+)-Fluoxetine 19.3 14.2 1.1 12.9 18.2 14.0 3.5 5.4 2.9 11.5 15.0 4.0 
R-(-)-Fluoxetine 19.2 2.7 20.7 6.2 3.8 0.5 0.3 2.7 14.5 14.2 3.5 5.8 
E1-Norfluoxetine 17.6 15.1 9.7 6.6 3.8 9.6 2.5 7.9 13.5 14.1 6.7 8.0 
E2-Norfluoxetine 1.9 6.8 10.7 20.3 10.5 3.4 0.7 10.7 7.3 6.5 11.4 6.2 
*-D indicates day 
**- the following concentrations were used: 10, 100 and 1000 ng L-1 in the case of compounds that were not enantioseparated 
29 
 
Table 8 Concentration of targeted compounds in wastewater samples during one week monitoring campaign  
 Concentration [ng L-1] 
 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Cocaine 403 ± 28 449 ± 60 420 ± 13 397 ± 28 452 ± 22 694 ± 23 634 ± 23 
Benzoylecgonine 997 ± 150 754 ± 90 788 ± 26 864 ± 112 950 ± 43 1604 ± 129 1537 ± 95 
Cocaethylene 4 ± 0 2 ± 0 2 ± 1 2 ± 0 4 ± 0 10 ± 1 9 ± 1 
R-(-)-Amphetamine 241 ± 62 169 ± 8 207 ± 39 202 ± 14 204 ± 10 224 ± 17 192 ± 11 
S-(+)-Amphetamine 171 ± 12 122 ± 7 154 ± 7 152 ± 14 140 ± 28 170 ± 17 147 ± 3 
R-(-)-Methamphetamine 6 ± 1 3 ± 11  6 ± 1 6 ± 2 6 ± 1 5 ± 1 4 ± 1 
S-(+)-Methamphetamine 2 ± 2 3 ± 5 6 ± 1 6 ± 4 3 ± 1 3 ± 2 4 ± 1 
E1-Mephedrone 42 ± 7 18 ± 6 32 ± 10 18 ± 3 22 ± 7 67 ± 15 53 ± 11 
E2-Mephedrone 29 ± 2 14 ± 5 28 ± 3 14 ± 6 18 ± 5 47 ± 6 44 ± 5 
R-(-)-MDA 7 ± 7 3 ± 4 10 ± 11 N.D. N.D. 4 ± 3 7 ± 2 
S-(+)-MDA N.D. N.D. 2 ± 4 3 ± 4 4 ± 8 13 ± 5 14 ± 7 
R-(-)-MDMA 109 ± 7 68 ± 5 45 ± 3 34 ± 2 45 ± 4 133 ± 9 186 ± 10 
S-(+)-MDMA 43 ± 4 26 ± 2 23 ± 2 19 ± 2 32 ± 1 84 ± 4 110 ± 6 
E1-MDEA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-MDEA 1 ± 0 1 ± 1 N.D.  N.D. 8 ± 16 N.D. 1 ± 1 
Heroin N.D. 26 ± 52 112 ± 223 68 ± 78 50 ± 64 147 ± 24 16 ± 32 
O-6-monoacetylmorphine 7 ± 4 2 ± 2 5 ± 4 2 ± 2 4 ± 4 7 ± 5 2 ± 2 
Morphine 653 ± 29 643 ± 65 713 ± 40 514 ± 18 640 ± 27 591 ± 63 595 ± 46 
Morphine-3β-D-glucuronide N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Ketamine 274 ± 17 235 ± 9 284 ± 22 250 ± 14 254 ± 8 287 ± 23 281 ± 14 
Benzylpiperazine 9 ± 7 65 ± 6 9 ± 3 9 ± 2 7 ± 1 7 ± 3 8 ± 3 
Temazepam 269 ± 78 320 ± 116 408 ± 55 233 ± 125 224 ± 133 256 ± 134 255 ± 119 
Diazepam 3 ± 6 2 ± 5 3 ± 3 41 ± 10 22 ± 6 3 ± 6 3 ± 4 
Nordiazepam 18 ± 11 9 ± 7 14 ± 11 12 ± 12 12 ± 10 4 ± 8 9 ± 8 
Nitrazepam 3 ± 5 29 ± 24 N.D. 4 ± 3 1 ± 2 2 ± 2 4 ± 8 
Oxazepam N.D. N.D. 184 ± 123 281 ± 198 73 ± 147 98 ± 195 83 ± 96 
7-amino-nitrazepam 2 ± 3 28 ± 28 1 ± 1 5 ± 8 5 ± 6 2 ± 3 13 ± 4 
Lorazepam 59 ± 59 N.D. 28 ± 35 9 ± 18 33 ± 27 N.D. 5 ± 9 
Anhydroecgonine methyl ester 5 ± 1 8 ± 2 8 ± 2 9 ± 2 8 ± 2 12 ± 1 12 ± 1 
E1-HMA 43 ± 29 N.D. N.D. N.D. N.D. 13 ± 26 45 ± 35 
E2-HMA 46 ± 4 11 ± 22 N.D. N.D. N.D. 12 ± 24 32 ± 22 
E1-HMMA 27 ± 7 14 ± 2 9 ± 1 7 ± 1 10 ± 2 23 ± 2 35 ± 3 
E2-HMMA 21 ± 5 12 ± 3 10 ± 1 9 ± 1 10 ± 2 27 ± 4 33 ± 2 
DHMA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Caffeine 184819 ± 14657 135883 ± 11735 173852 ± 8241 171064 ± 8077 171958 ± 5199 169130 ± 5162 151231 ± 5249 
1,7-Dimethylxanthine 107717 ± 4786 85882 ± 2418 137196 ± 28326 114869 ± 46279 75413 ± 6759 107717 ± 12820 106272 ± 31432 
(-)-Nicotine 6152 ± 4540 3340 ± 653 7810 ± 4460 8562 ± 7806 6375 ± 3844 4872 ± 244 5549 ± 1807 
Cotinine 2137 ± 324 1882 ± 202 2116 ± 35 2071 ± 83 2194 ± 67 2266 ± 115 2437 ± 114 
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Creatinine 679 ± 51 326 ± 87 355 ± 53 379 ± 124 338 ± 79 250 ± 58 330 ± 59 
Codeine 2475 ± 56 1914 ± 269 2235 ± 247 1984 ± 195 2079 ± 134 1964 ± 184 1929 ± 257 
Oxycodone 11 ± 2 33 ± 30 16 ± 6 14 ± 8 15 ± 4 11 ± 3 18 ± 7 
Noroxycodone 21 ± 18 33 ± 23 13 ± 16 15 ± 10 33 ± 5 35 ± 12 25 ± 6 
Hydrocodone N.D. 22 ± 26 14 ± 29 10 ± 20 11 ± 22 38 ± 45 10 ± 20 
Oxymorphone 14 ± 12 46 ± 35 20 ± 4 18 ± 2 18 ± 12 12 ± 9 19 ± 3 
Dihydrocodeine 449 ± 37 437 ± 83 442 ± 19 380 ± 40 427 ± 36 419 ± 61 406 ± 59 
Methadone 54 ± 6 50 ± 11 54 ± 2 53 ± 2 56 ± 4 59 ± 4 51 ± 5 
EDDP 126 ± 13 105 ± 10 117 ± 11 106 ± 6 123 ± 16 112 ± 18 122 ± 8 
E1-Venlafaxine 94 ± 9 74 ± 12 86 ± 9 92 ± 12 94 ± 9 102 ± 3 105 ± 3 
E2-Venlafaxine 122 ± 3 88 ± 8 102 ± 11 97 ± 11 101 ± 12 109 ± 3 92 ± 7 
Vardenafil 7 ± 9 N.D. N.D. N.D. N.D. N.D. N.D. 
E1-Norephedrine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-Norephedrine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E1-PMA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-PMA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Normorphine 148 ± 23 131 ± 79 154 ± 16 181 ± 69 193 ± 52 152 ± 30 145 ± 27 
Dihydromorphine 23 ± 5 43 ± 4 25 ± 10 27 ± 3 32 ± 15 15 ± 5 24 ± 5 
D1-Tramadol 704 ± 17 720 ± 30 740 ± 48 766 ± 12 692 ± 32 772 ± 40 798 ± 39 
D2-Tramadol 640 ± 2 666 ± 21 678 ± 13 621 ± 65 672 ± 26 651 ± 37 595 ± 22 
O-Desmethyltramadol 836 ± 76 873 ± 25 950 ± 21 882 ± 20 801 ± 16 849 ± 3 860 ± 9 
Zolpidem 1 ± 1 1 ± 2 N.D. N.D. N.D. N.D. N.D. 
Amitriptyline 234 ± 40 126 ± 17 257 ± 29 227 ± 13 232 ± 59 218 ± 6 245 ± 22 
Norketamine 47 ± 10 39 ± 9 32 ± 4 57 ± 1 50 ± 14 45 ± 7 37 ± 8 
Sildenafil 30 ± 9 3 ± 0 21 ± 7 13 ± 0 12 ± 2 11 ± 2 20 ± 7 
(+)-Ephedrine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
(-)-Ephedrine and (-)-Ψephedrine 23 ± 10 21 ± 3 28 ± 4 24 ± 3 27 ± 3 18 ± 7 17 ± 2 
(+)-Ψephedrine 201 ± 15 191 ± 10 169 ± 22 163 ± 20 160 ± 19 136 ± 13 153 ± 3 
Desmethylvenlafaxine-E1 291 ± 2 296 ± 13 292 ± 14 289 ± 10 315 ± 7 269 ± 15 305 ± 15 
Desmethylvenlafaxine-E2 250 ± 6 233 ± 9 235 ± 8 191 ± 4 225 ± 15 211 ± 12 215 ± 26 
E1-Zopiclone N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-Zopiclone N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
S-(+)-fluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
R-(-)-fluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E1-Norfluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-Norfluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
N.D - not detected 
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Table S1 Selected analytes and their properties (MW molecular weight, Exp experimental, Pred predicted, a extracted from [38] , b predicted using 
ACD/labs software (http://www.chemspider.com). 
Compound CAS Formula MW pKa  LogP LogDb  Supplier 
        Exp.a Pred.a Exp.a Pred.b pH 5.5 pH 7.4  
Cocaine 50-36-2 C17H21NO4 303.4 
8.6 
(15°) 
8.8 2.3c 3.1±0.4 0.1 1.5 
LGC (Cerilliant 
product) 
Benzoylecgonine 519-09-5 C16H19NO4 289.3 - 3.1, 9.5 - 2.7±0.4 0.2 0.2 Sigma-Aldrich 
Cuscohygrine 454-14-8 C13H24N2O 224.3 - - - 0.7±0.3 -3.4 -3.2 TRC 
Cocaethylene 529-38-4 C18H23NO4 317.4 - - - 2.8 -0.2 1.1 
Sigma Aldrich 
(Cerilliant product) 
Anhydroecgonine  
methyl ester 
43021-26-7 C10H15NO2 181.2 - - - 1.7±0.3 -0.7 1.0 
Sigma Aldrich 
(Cerilliant product) 
(±)-Amphetamine 300-62-9 C9H13N 135.2 
10.1 
(20°) 
10.0 1.8 1.8±0.2 -1.3 -0.6 
LGC(Cerilliant 
product) 
(±)-Methamphetamine  4846-07-5 C10H15N 149.2 
9.9 
(25°) 
10.2 2.1 1.9±0.2 -1.1 -0.8 
LGC (Cerilliant 
product) 
S-(+)- 
Methamphetamine 
537-46-2 C10H15N 149.2 
9.9 
(25°) 
10.2 2.1 1.9±0.2 -1.1 -0.8 Cerilliant 
BZP 
(benzylpiperazine) 
2759-28-6 C11H16N2 176.3 - - - 1.4±0.4 -1.6 -0.4 LGC 
TFMPP (1-(3-
trifuoromethylphenyl)pi
perazine) 
- C11H13F3N2 230.2 - - - 2.4±0.5 -0.4 1.2 LGC 
(±)-Mephedrone 
1189726-22-
4 
C11H15NO 177.7 - - - 1.9±0.3 -0.0 1.5 
Sigma-Aldrich 
(Cerilliant product) 
PMA (p-
Methoxyamphetamine
) 
3706-26-1 C10H15NO 165.0 - - - 1.7±0.2 -1.4 -0.8 LGC 
(±)-MDA (3,4-
methylenedioxyamphe
tamine) 
4764-17-4 C10H13NO2 179.2 
9.7 
(25°) 
10.0 1.6 1.7±0.3 -1.4 -0.8 
LGC (Cerilliant 
product) 
(±)-MDMA (3,4-
methylenedioxymetha
mphetamine) 
42542-10-9 C11H15NO2 193.2 - 10.1 
-
1.6,1.9 
1.8±0.3 -1.3 -0.9 LGC  
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(±)-MDEA (3,4-
methylenedioxyethyla
mphetamine) 
82801-81-8 C12H17NO2 207.3 - - - 2.7±0.3 -0.4 0.3 
LGC (Cerilliant 
product) 
D,L-HMA (d,l-4-
Hydroxy-3-
methoxyamphetamine
) 
13062-61-8 C10H15NO2 181.2 - - - - - - Kinesis  
D,L-HMMA (d,l-4-
Hydroxy-3-
methoxymethampheta
mine) 
438625-58-2 C11H17NO2 195.2 - - - 1.4 -1.7 -1.2 Kinesis  
D,L-3,4-HHMA (2-
(3,4-
Dihydroxyphenyl)-N-
methylpropylamine) 
15398-87-5 C10H15NO2 181.2 - - - - - - Kinesis  
Caffeine 58-08-2 C8H10N4O2 194.2 
10.4 
(40°) 
-0.9  -0.1 -0.1±0.4 -0.1 -0.1 Sigma-Aldrich 
1,7-dimethylxanthine 
(Paraxanthine) 
611-59-6 C7H8N4O2 180.2 - -  - -1.6±0.9 -1.6 -1.6 Sigma-Aldrich 
(-)-Nicotine 54-11-5 C10H14N2 162.2 3.1 8.9   1.2 0.7±0.3 -2.1 -0.5 Sigma-Aldrich 
(-)-Cotinine 486-56-6 C10H12N2O 176.2 - - - -0.2±0.4 -0.3 -0.2 
Sigma Aldrich 
(Cerilliant product) 
Heroin 561-27-3 C21H23NO5 369.4 
7.9 
(25°) 
9.1 1.6 1.5±0.7 -0.8 0.9 
Sigma Aldrich 
(Cerilliant product) 
6-acetylmorphine 2784-73-8 C19H21NO4 327.4 - 10.2, 9.1 1.9,1.3 0.4±0.7 -1.7 -0.1 
Sigma Aldrich 
(Cerilliant product) 
Codeine 76-57-3 C18H21NO3 299.4 
8.2 
(25°) 
13.8, 9.2 
1.2, 
1.3 
1.2±0.7 -1.4 0.3 Sigma-Aldrich 
Norcodeine 467-15-2 C17H19NO3 285.3 - 
13.8, 
10.1 
1.0, 
1.0 
0.9±0.7 -2.1 -1.1 
Sigma Aldrich 
(Cerilliant product) 
Oxycodone 76-42-6 C18H21NO4 315.4 - 13.6, 8.2 
1.0, 
1.0 
1.7±0.6 -0.5 1.2 
Sigma Aldrich 
(Cerilliant product) 
Noroxycodone 52446-25--0 C17H19NO4 301.2 - 13.6, 9.5 -  0.2 -2.7 -1.1 
Sigma Aldrich 
(Cerilliant product) 
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(-)-Oxymorphone 76-41-5 C17H19NO4 301.3 -  10.1, 8.2 -  0.9±0.5 -1.1 0.5 
Sigma Aldrich 
(Cerilliant product) 
D-(-)-Morphine 57-27-2 C17H19NO3 285.3 
8.2 
(25°) 
10.3, 9.1 0.9 0.4±0.7 -2.1 -0.4 
Sigma Aldrich 
(Cerilliant product) 
Normorphine 466-97-7 C16H17NO3 271.3 - 10.5, 9.8 - 0.1±0.7 -2.9 -1.8 
Sigma Aldrich 
(Cerilliant product) 
Dihydromorphine 509-60-4 C17H21NO3 287.4 - 10.3, 9.2 - 0.6±0.4 -2.0 -0.4 
Sigma Aldrich 
(Cerilliant product) 
Hydrocodone 125-29-1 C18H21NO3 299.4 - 18.0, 8.6 1.2 1.8±0.5 -0.9 0.7 
Sigma Aldrich 
(Cerilliant product) 
Morphine-3β-D-
glucuronide 
20290-09-9 C23H27NO9 461.5 - 
12.2, 
10.8 
- -2.0±0.8 -4.5 -4.6 
Sigma Aldrich 
(Cerilliant product) 
(±)-Methadone 76-99-3 C21H27NO 309.4 
8.9 
(25°) 
18.8, 9.1 3.9 4.2±0.3 1.2 2.6 
Sigma Aldrich 
(Cerilliant product) 
(±)-EDDP (2-
ethylidene-1,5-
dimethyl-3,3-
diphenylpyrrolidine) 
66729-78-0 C20H23N 277.4 - 9.6 - 5.4 3.6 4.9 
LGC (Cerilliant 
product) 
(±)-cis-Tramadol 36282-47-0 C16H25NO2 263.4 9.4 13.8, 9.2 2.4 2.5±0.3 -0.5 0.5 Sigma-Aldrich 
N-Desmethyltramadol 
1018989-94-
0 
C15H23NO2 249.4 - 13.8, 9.9 - 1.7 -1.4 -1.1 LGC 
(+)-O-
Desmethyltramadol 
185453-02-5 C15H23NO2 249.4 - 9.6, 9.0 - 1.7 -1.3 -0.2 LGC 
Temazepam 846-50-4 
C16H13ClN2
O2 
300.7 - 
10.7, -
1.4 
2.2 2.1±0.9 2.1 2.1 
Sigma Aldrich 
(Cerilliant product) 
Diazepam 439-14-5 
C16H13ClN2
O 
284.7 3.4 2.9 2.8 2.9±0.9 2.9 2.9 
Sigma Aldrich 
(Cerilliant product) 
Nordiazepam  1088-11-5 
C15H11ClN2
O 
270.7 -  12.3, 2.8 2.5b 3.1±0.5 3.1 3.1 
Sigma Aldrich 
(Cerilliant product) 
Nitrazepam 146-22-5 C15H11N3O3 281.3 -  11.9, 2.6 2.2 2.2±0.5 2.2 2.2 
LGC (Cerilliant 
product) 
7-aminonitrazepam 4928-02-3 C15H13N3O 251.3 -  -  -  1.1±0.8 1.0 1.1 
Sigma Aldrich 
(Cerilliant product) 
Oxazepam 604-75-1 
C15H11ClN2
O2 
286.7 -  
10.6, -
1.5 
-  2.3±0.5 2.3 2.3 
Sigma-Aldrich 
(Cerilliant product) 
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(±)-Lorazepam 846-49-1 
C15H10Cl2N2
O2 
321.2 13 
10.6, -
2.2 
2.4 2.5±0.5 2.5 2.5 
Sigma-Aldrich 
(Cerilliant product) 
Amitriptyline 549-18-8 C20H23N 277.4 9.4 9.8 4.9 4.9±0.6 1.9 3.1 Sigma-Aldrich 
Nortriptyline 894-71-3 C19H21N 263.4 - 10.5 - 5.6±0.3 2.6 3.2 Sigma-Aldrich 
Fluoxetine 59333-67-4 C17H18F3NO 309.3 - 9.8 4.0 4.1±0.4 1.0 1.6 
LGC (Cerilliant 
product) 
R-(-)-fluoxetine 114247-09-5 C17H18F3NO 309.3 - 9.8 4.0 4.1±0.4 1.0 1.6 Sigma-Aldrich 
Norfluoxetine 107674-50-0 C16H16F3NO 295.3 - 9.8 - 4.4±0.4 1.4 2.7 
LGC (Cerilliant 
product) 
(±)-Venlafaxine 99300-78-4 C17H27NO2 277.4 - 14.4, 8.9 - 2.9±0.3 -0.1 1.2 Sigma-Aldrich 
O-Desvenlafaxine 300827-87-6 C16H25NO2 263.0 - 10.1, 8.9 - 2.3±0.3 -0.7 0.5 Sigma-Aldrich 
Zolpidem 
 
 
99294-93-6 C19H21N3O 307.4 6.2 5.6 1.2 3.1±0.6 1.9 3.0 
Sigma Aldrich 
(Cerilliant product) 
(±)-Zopiclone 43200-80-2 
C17H17ClN6
O6 
388.8 - 13.0, 6.9 0.8 -0.3±1.3 -1.5 -0.4 LGC 
(±)-Ketamine 1867-66-9 C13H16ClNO 237.7 - 18.8, 7.4 2.9 2.2±0.6 1.2 2.1 Sigma-Aldrich 
(±)-Norketamine  79499-59-5 C12H14ClNO 223.7 - 18.7, 7.5 - 1.9±0.5 1.1 1.9 
Sigma Aldrich 
(Cerilliant product) 
Sildenafil 139755-83-2 C22H30N6O4S 474.6 - 7.3, 6.0 1.9 2.3±1.4 1.6 2.2 
Sigma Aldrich 
(Cerilliant product) 
Vardenafil 
224789-
1515-5 
C23H32N6O4S 488.6 - 8.0, 6.2 1.4 2.6±1.2 1.0 2.5 
Sigma Aldrich 
(Cerilliant product) 
(±)-Pentobarbital  76-74-4 C11H18N2O3 226.3 
8.1 
(25°) 
8.5 2.1 2.0±0.2 2.0 1.9 
Sigma-Aldrich 
(Cerilliant product) 
Secobarbital 29071-21-4  C12H18N2O3 238.3 7.8 8.5 1.9 2.2±0.2 2.2 2.0 
Sigma-Aldrich 
(Cerilliant product) 
Ephedrine 50-98-6 C10H15NO 165.2 
10.3 
(0°) 
13.9, 9.5 1.1 1.0±0.3 -2.0 -0.9 Sigma-Aldrich 
(1R,2R)-(-)-
Pseudoephedrine 
321-97-1 C10H15NO 165.2 
10.3 
(0°) 
13.9, 9.5 1.1 1.0±0.3 -2.0 -0.9 Sigma-Aldrich 
(±)-Norephedrine 154-41-6 C9H13NO 151.2 
9.4 
(20°) 
13.9, 9.4 0.7 0.8±0.3 -2.2 -1.1 Sigma-Aldrich 
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Table S2 Studied mobile phase compositions with CHIRALPAK® CBH HPLC  
% MP modifiers 
Conc. 
NH4OAc 
(mM) 
pH 
10% IPA 1.0 5.0 
10% MeOH 1.0 6.6 
10% ACN 1.0 6.4 
5% IPA 1.0 6.2 
5% MeOH 1.0 6.7 
10% MeOH 5.0 6.8 
10% MeOH 10.0 6.9 
10% MeOH 1.0 6. 7 
10% MeOH 2.5 6.6 
10% MeOH 1.0 6.2 
15% MeOH 1.0 6.4 
 
Table S3 Studied mobile phase compositions with CHIROBIOTIC V 
% H2O %FA 
Conc. 
NH4OAc 
(mM) 
pH 
1 0.005 4 6.8 
5 0.005 4 6.8 
20 0.005 4 6.5 
80 0.005 4 5.2 
25 - 0 0.005 4   
0 0 0   
1 0.005 1 5.9 
1 0.005 10 7.4 
1 0.001 1 7.3 
 
Table S4 Studied mobile phase compositions with CHIROBIOTIC T (mobile phases with 
pH<3 were not tested due to the extreme pH not suitable for the studied chiral column)  
% H2O %FA 
Conc. 
NH4OAc 
(mM) 
pH 
1 0.005 4 6.8 
0 0 0   
5 0.005 4 6.8 
20 0.005 4 6.5 
80 0.005 4 5.2 
80 0 20 6.7 
0 - 100 0.005 4   
1 0.005 1 5.9 
1 0.005 10 7.4 
1 0.001 1 7.3 
1 0.001 10 7.9 
1 0.001 4 7.6 
1 0.01 1 5.2 
1 0.01 10 6.9 
1 0.01 4 6.4 
1 1 1 2. 9 
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1 1 10 3.9 
1 1 4 3.5 
5 0.005 1 5.6 
5 0.005 10 7.0 
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Table S5 Validation parameters -instrumental precision 
 Intra-day RSD% (n=4) Inter-day RSD% (n=3) 
 5 
µg/L** 
5 
µg/L 
5 
µg/L 
50 
µg/L 
50 
µg/L 
50 
µg/L 
500 
µg/L 
500 
µg/L 
500 
µg/L 
5 
µg/L 
50 
µg/L 
500 µg/L 
  D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3    
Cocaine 1.2 2.3 5.3 2.2 4.0 0.5 3.2 3.7 0.5 2.9 2.3 2.5 
Benzoylecgonine 3.1 4.1 2.6 6.2 2.9 2.7 1.1 1.8 1.7 3.3 3.9 1.5 
Cocaethylene 7.9 3.5 4.8 0.2 0.4 0.6 0.2 3.8 2.4 5.4 0.4 2.1 
R-(-)-Amphetamine 4.8 5.8 3.0 2.3 3.1 0.1 3.9 4.7 3.1 4.5 1.9 3.9 
S-(+)-Amphetamine 3.7 5.3 6.5 4.6 3.3 4.3 3.2 4.1 3.4 5.2 4.1 3.6 
R-(-)-Methamphetamine 6.0 5.8 6.3 3.9 5.5 2.3 3.0 5.1 2.8 6.0 3.9 3.7 
S-(+)-Methamphetamine 2.4 2.3 7.7 2.7 0.7 2.1 1.1 4.8 3.4 4.1 1.8 3.1 
E1-Mephedrone 9.3 6.7 5.5 1.9 5.7 5.4 2.9 5.5 4.4 7.1 4.3 4.3 
E2-Mephedrone 3.5 6.7 1.1 3.6 2.5 2.7 9.3 4.3 2.2 3.8 3.0 5.2 
R-(-)-MDA 6.9 1.3 2.7 0.4 5.6 0.1 1.5 0.3 1.6 3.6 2.1 1.1 
S-(+)-MDA 5.7 3.2 6.4 8.0 8.9 3.1 0.3 1.1 6.1 5.1 6.7 2.5 
R-(-)-MDMA 2.5 5.5 2.0 1.8 6.4 3.9 4.8 3.7 6.1 3.3 4.0 4.9 
S-(+)-MDMA 3.5 1.1 4.3 0.5 1.8 1.3 2.5 1.5 2.7 3.0 1.2 2.3 
E1-MDEA 8.6 5.3 5.9 2.2 3.8 1.1 6.1 4.3 0.1 6.6 2.4 3.5 
E2-MDEA 3.6 2.3 10.3 5.3 1.1 0.4 5.6 1.9 0.7 5.4 2.3 2.7 
Heroin 6.7 17.8 0.0 2.4 11.3 29.2 11.5 13.9 13.4 8.2 14.3 13.0 
O-6-monoacetylmorphine 9.0 9.2 12.4 0.0 1.8 11.0 1.2 10.7 1.4 10.2 4.3 4.4 
Morphine 12.1 4.4 10.6 13.5 5.5 7.9 11.0 1.2 4.4 9.1 8.9 5.5 
Morphine-3β-D-
glucuronide 
14.8 19.9 2.5 4.6 16.8 20.0 8.3 6.6 13.3 12.4 13.8 9.4 
Ketamine 4.0 5.4 7.1 2.0 1.4 1.9 1.3 1.8 1.6 5.5 1.8 1.5 
Benzylpiperazine 6.8 2.4 2.2 6.6 2.5 10.8 1.1 1.8 3.1 3.8 6.6 2.0 
Temazepam 5.9 7.2 7.9 0.7 2.2 6.4 4.4 4.1 0.3 7.0 3.1 2.9 
Diazepam 4.9 4.8 6.3 1.2 2.8 4.4 2.3 1.7 1.3 5.3 2.8 1.8 
Nordiazepam 7.0 8.4 7.3 5.1 7.5 3.6 2.2 1.6 7.4 7.6 5.4 3.7 
Nitrazepam 7.1 4.2 0.8 7.3 7.8 2.9 8.5 5.6 4.7 4.0 6.0 6.3 
Oxazepam 7.5 7.7 7.3 2.7 5.5 0.0 1.7 1.6 0.6 7.5 2.7 1.3 
7-amino-nitrazepam 3.4 3.6 6.5 4.7 3.3 1.8 4.7 5.0 0.8 4.5 3.2 3.5 
Lorazepam 1.9 8.4 21.2 7.5 6.9 1.6 4.8 6.6 7.2 10.5 5.3 6.2 
Anhydroecgonine methyl 
ester 
6.8 4.2 2.2 4.4 2.9 4.0 0.7 6.5 2.0 4.4 3.8 3.1 
E1-HMA 11.3 5.6 6.3 5.3 6.7 9.1 7.4 4.9 2.1 7.7 7.1 4.8 
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E2-HMA 6.1 1.7 1.1 3.1 0.4 2.5 8.9 6.3 9.0 3.0 2.0 8.1 
E1-HMMA 5.3 8.3 4.1 0.8 6.5 6.6 8.2 4.2 1.7 5.9 4.6 4.7 
E2-HMMA 6.6 5.7 9.4 2.4 3.3 7.4 3.8 4.0 4.6 7.2 4.4 4.1 
DHMA 8.1 4.5 9.2 3.2 12.3 5.4 3.5 2.6 1.7 7.3 7.0 2.6 
Caffeine 1.9 0.9 4.4 3.0 12.9 4.4 4.5 3.6 1.3 2.4 6.7 3.1 
1,7-dimethylxanthine 1.5 8.0 7.7 2.8 15.3 6.6 0.2 0.3 0.9 5.7 8.2 0.5 
Nicotine 1.6 9.8 8.6 2.7 13.4 2.7 1.7 1.6 1.8 6.7 6.3 1.7 
Cotinine 1.1 2.6 6.5 7.0 11.8 2.4 0.1 1.9 4.1 3.4 7.1 2.0 
Creatinine 5.2 6.0 7.4 2.3 0.1 1.2 1.1 0.8 1.6 6.2 1.2 1.2 
Codeine 11.7 7.3 2.3 7.6 1.7 6.9 6.0 2.6 4.8 7.1 5.4 4.5 
Oxycodone 8.3 7.3 4.0 2.5 10.5 6.6 5.6 8.8 5.3 6.5 6.5 6.6 
Noroxycodone 1.91 3.3 4.0 6.0 2.3 3.8 1.4 5.8 2.0 3.1 4.0 3.1 
Hydrocodone 3.8 5.2 4.7 1.3 7.8 4.1 2.0 0.6 1.3 4.6 4.4 1.3 
Oxymorphone 7.3 6.8 5.5 0.4 4.5 2.8 2.1 5.9 2.1 6.5 2.6 3.4 
Dihydrocodeine 6.8 8.2 7.4 6.6 8.7 3.4 0.5 2.0 0.6 7.4 6.2 1.0 
Methadone 0.6 2.1 1.6 2.5 1.0 3.1 1.3 0.9 0.2 1.4 2.2 0.8 
EDDP 5.8 4.8 5.1 1.7 2.7 2.2 0.5 1.3 1.5 5.2 2.2 1.1 
E1-Venlafaxine 7.1 3.1 7.4 3.4 2.0 0.8 0.4 1.4 0.9 5.9 2.1 0.9 
E2-Venlafaxine 6.1 2.4 0.0 1.9 2.9 3.6 0.5 1.4 0.9 2.8 2.8 0.9 
Vardenafil 25.0 7.3 21.8 5.1 1.1 5.1 0.1 0.8 3.1 18.0 3.8 1.3 
E1-Norephedrine 5.9 7.1 3.1 2.7 6.9 5.7 2.2 1.3 1.1 5.4 5.1 1.5 
E2-Norephedrine 5.4 3.1 4.4 2.4 4.7 3.6 3.4 5.2 2.1 4.3 3.6 3.6 
E1-PMA 2.7 8.4 5.6 1.2 8.6 6.1 2.6 0.3 0.4 5.6 5.3 1.1 
E2-PMA 4.6 5.4 4.5 4.6 3.9 2.6 3.1 1.6 1.1 4.9 3.7 1.9 
Normorphine 4.6 13.3 0.0 20.0 0.5 8.2 3.8 0.1 15.8 6.0 9.5 6.6 
Dihydromorphine 18.1 3.0 5.3 15.7 20.0 4.8 8.9 4.9 11.0 8.8 13.5 8.3 
D1-Tramadol 11.2 7.1 5.6 3.4 4.1 3.6 5.1 0.9 2.5 8.0 3.7 2.8 
D2-Tramadol 2.4 6.8 10.7 13.8 12.4 7.1 2.2 10.0 1.1 6.7 11.1 4.4 
O-desmethyltramadol 12.9 10.9 7.2 6.2 3.0 3.5 8.3 5.2 3.2 10.3 4.2 5.6 
Zolpidem 15.7 16.3 1.6 1.2 0.1 1.1 3.3 3.4 0.2 11.2 0.8 2.3 
Amitriptyline 0.0 10.1 8.3 3.1 6.0 11.3 3.4 3.4 3.4 6.1 6.8 3.4 
Norketamine 2.7 6.9 6.0 3.4 1.1 3.5 2.6 2.4 1.4 5.2 2.7 2.1 
Sildenafil 5.4 15.7 10.9 4.8 15.3 5.7 7.6 0.9 1.5 10.7 8.6 3.3 
(+)-Ephedrine 6.9 3.5 6.5 4.3 5.7 3.2 6.3 1.0 3.4 5.6 4.4 3.6 
(-)-Ephedrine and (-)-
Ψephedrine 
2.6 2.7 4.1 3.6 3.1 2.3 6.4 0.7 4.4 3.1 3.0 3.8 
(+)-Ψephedrine 10.6 6.2 5.6 5.9 0.5 2.4 3.4 9.1 3.2 7.4 2.9 5.3 
Desmethylvenlafaxine-E1 18.2 7.4 5.2 5.3 7.2 0.7 1.9 8.1 2.0 10.3 4.4 4.0 
Desmethylvenlafaxine-E2 5.4 4.5 4.0 5.7 12.5 6.4 2.8 2.0 3.9 4.7 8.2 2.9 
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E1-Zopiclone 18.2 19.7 15.8 14.2 16.2 12.2 11.4 10.7 8.7 17.9 14.2 10.3 
E2-Zopiclone 17.9 19.3 16.7 12.6 18.6 18.0 14.6 13.8 8.5 17.9 16.4 12.3 
S-(+)-Fluoxetine 18.3 6.9 4.9 6.0 19.0 9.3 13.6 14.4 2.4 10.0 11.4 10.2 
R-(-)-Fluoxetine 16.5 15.9 10.2 13.0 1.3 16.9 1.7 9.3 2.4 14.2 10.4 4.5 
E1-Norfluoxetine 11.5 4.4 18.4 5.9 8.2 0.8 5.1 3.1 3.4 11.4 5.0 3.9 
E2-Norfluoxetine 10.2 14.3 16.6 15.5 9.8 13.8 17.6 8.0 0.5 13.7 13.1 8.7 
*-D indicates day 
**- the following concentrations were used: 10, 100 and 1000 ng/L in the case of compounds that were not enantioseparated 
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Table S6 Validation parameters –ion suppression 
 Signal suppression (%) (n=4) 
Cocaine -69.0 ± 25.8 
Benzoylecgonine -6.1 ± 1.5 
Cocaethylene -27.5 ± 5.2 
R-(-)-Amphetamine 37.9 ± 9.7 
S-(+)-Amphetamine 53.4 ± 9.4 
R-(-)-Methamphetamine -28.5 ± 12.5 
S-(+)-Methamphetamine -6.4 ± 9.2 
E1-Mephedrone -22.3 ± 11.8 
E2-Mephedrone -40.2 ± 14.0 
R-(-)-MDA -15.3 ± 1.4 
S-(+)-MDA -12.5 ± 1.8 
R-(-)-MDMA -43.9 ± 7.4 
S-(+)-MDMA -57.5 ± 8.2 
E1-MDEA -33.9 ± 2.0 
E2-MDEA -58.1 ± 6.6 
Heroin -5.1 ± 10.3 
O-6-monoacetylmorphine -85.2 ± 18.8 
Morphine -58.1 ± 18.5 
Morphine-3β-D-glucuronide 99.7 ± 0.6 
Ketamine 12.5 ± 11.2 
Benzylpiperazine -50.1 ± 5.3 
Temazepam 21.5 ± 4.3 
Diazepam -37.5 ± 7.7 
Nordiazepam -34.9 ± 1.5 
Nitrazepam 45.7 ± 2.6 
Oxazepam 47.7 ± 4.2 
7-amino-nitrazepam 70.9 ± 6.7 
Lorazepam 49.3 ± 10.5 
Anhydroecgonine methyl ester -90.4 ± 2.9 
E1-HMA -50.4 ± 6.2 
E2-HMA -68.7 ± 13.9 
E1-HMMA -81.5 ± 33.7 
E2-HMMA -76.7 ± 15.0 
DHMA 95.4 ± 10.1 
Caffeine 57.3 ± 12.3 
1,7-dimethylxanthine 59.3 ± 9.4 
Nicotine -9.4 ± 7.1 
Cotinine 49.0 ± 10.9 
Creatinine 70.1 ± 2.3 
Codeine -5.2 ± 7.2 
Oxycodone -58.5 ± 11.5 
Noroxycodone -58.6 ± 7.8 
Hydrocodone -50.8 ± 7.6 
Oxymorphone -74.7 ± 10.5 
Dihydrocodeine -6.6 ± 11.6 
Methadone 37.6 ± 19.9 
EDDP 23.9 ± 1.8 
E1-Venlafaxine -19.3 ± 4.8 
E2-Venlafaxine -12.1 ± 9.5 
Vardenafil 15.7 ± 10.8 
E1-Norephedrine 63.4 ± 2.8 
E2-Norephedrine 21.5 ± 4.6 
E1-PMA -21.7 ± 7.9 
E2-PMA -38.8 ± 4.1 
Normorphine 63.2 ± 11.0 
Dihydromorphine 60.0 ± 10.2 
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D1-Tramadol 22.1 ± 1.5 
D2-Tramadol 8.8 ± 6.6 
O-desmethyltramadol 46.7 ± 3.0 
Zolpidem -72.1 ± 3.2 
Amitriptyline -23.5 ± 0.6 
Norketamine -52.1 ± 2.4 
Sildenafil -49.9 ± 11.8 
(+)-Ephedrine -78.2 ± 4.6 
(-)-Ephedrine and (-)-
Ψephedrine 
-72.3 ± 7.5 
(+)-Ψephedrine -76.7 ± 16.3 
Desmethylvenlafaxine-E1 -6.3 ± 2.0 
Desmethylvenlafaxine-E2 -31.1 ± 16.4 
E1-Zopiclone -33.2 ± 5.6 
E2-Zopiclone -41.0 ± 4.5 
S-(+)-Fluoxetine 1.5 ± 0.1 
R-(-)-Fluoxetine 3.2 ± 2.5 
E1-Norfluoxetine -4.3 ± 0.7 
E2-Norfluoxetine -11.0 ± 0.8 
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Figure S1 CBH column - enantiomeric resolution of studied analytes in a mobile phase containing acetonitrile as organic modifier (mobile phase 
composition: 1mM ammonium acetate/acetonitrile 9:1). 
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Figure S2 CBH column - enantiomeric resolution of studied analytes in a mobile phase containing isopropanol as organic modifier (mobile phase 
composition: (a) 1mM ammonium acetate/isopropanol 9:1 and (b) 1mM ammonium acetate/isopropanol 9.5:0.5).  
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Figure S3 CBH column - enantiomeric resolution of studied analytes in mobile phases containing: (a) 1 mM ammonium acetate/methanol 9.5:0.5, (b) 1 
mM ammonium acetate/methanol 9:1, (c) 2.5 mM ammonium acetate/methanol 9:1, (d) 5 mM ammonium acetate /methanol 9:1 and (e) 10 mM 
ammonium acetate /methanol 9:1.
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Figure S4 CBH column - Impact of different percentanges of modifiers on retention time 
of analytes (NH4OAc: ammonium acetate, IPA: isopropanol, ACN: acetonitrile, MeOH: 
methanol). 
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Figure S5 Chirobiotic T column - overview of the separation for the targeted analytes (MeOH: 
methanol, NH4OAc: ammonium acetate, FA: formic acid). 
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Figure S6 Chirobiotic T column - separation of oxazepam and lorazepam (MeOH: methanol, 
NH4OAc: ammonium acetate, FA: formic acid. 
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